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Radiation-induced vascular disease is a well known phenomenon, which has 
already been described in 1899.1 Thereafter, several reports and cohort studies have 
documented the local vascular consequences of radiation therapy (RT).2-6 Acute 
vascular sequelae consist e.g. of (carotid) artery rupture, that is seen sporadically after 
RT on the neck in patients with head and neck cancer or lymphoma.7 Late delayed 
vascular complications are more frequent and generally occur many years after RT 
(range 1 to > 20 years).3,8 These late complications can occur at different locations than 
those of classical atherosclerosis and are related to the former RT-field. Among these, 
femoral artery and subclavian artery occlusions can occur after RT on the pelvis and 
the supraclavicular region, respectively. However, the relation between an ischemic 
stroke and previous RT on the neck is not always appreciated. To illustrate this entity, 
the clinical vignette of a patient with radiation-induced ischemic stroke is presented.
Patient A, a 78-year-old man, noticed sudden-onset weakness of the right side of 
his body in December 2003. In early 1997, he was curatively treated for a T2N0M0 
laryngeal carcinoma with RT (66 Gy in 33 fractions). No recurrence had occurred 
during the oncological follow-up. He had stopped smoking since the diagnosis of 
laryngeal carcinoma in 1997. No other cardiovascular risk factors were present. At the 
emergency room, neurological examination showed a normal level of consciousness 
and unimpaired language functions, slight weakness of the right arm and face, and no 
other abnormalities. 
He was admitted to the stroke care unit under the suspicion of a stroke located in the 
territory of the medial cerebral artery (MCA). A cerebral CT-scan confirmed a recent 
small cortical infarction in the left parietal lobe. The patient was then given aspirin 300 
mg daily for two weeks after which it was lowered to the permanent dose of 100 mg 
daily.
Duplex examination and MR-angiography of the cerebropetal arteries showed a 
significant stenosis (more than 70%) of the left internal carotid artery (ICA). Extensive 
screening of other risk factors did not reveal any abnormalities.
His right-sided weakness recovered during the admission. Considering the RT in the 
past, carotid endarterectomy (CEA) was deferred because of extensive fibrotic changes 
in the neck.  In order to treat the symptomatic high-grade ICA stenosis, it was decided 
to perform a carotid angioplasty with stent placement (CAS) (figure 1). The procedure 
was performed without complications and during repeated outpatient visits, the 
patient did not report any new neurological deficits.
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Figure 1. Left: Digital subtraction angiogram of the left internal carotid artery with a stenosis of more than 
70% (arrow) distal to the bifurcation. Right:  A clear improvement is visible after carotid angioplasty with 
stent placement.
Due to more successful RT and chemotherapy, the survival of many oncological 
patients has improved substantially.9,10 The downside of this success is the occurrence 
of long-term treatment related complications. Vascular disease, like ischemic stroke, 
is one of the most important determinants of late morbidity and mortality after RT. 
The magnitude of a possibly increased risk of future stroke and TIA due to RT on the 
neck can not be extracted from the data and cases published so far. Evidence for an 
increased risk of stroke was provided by a cohort study by Elerding et al.; although they 
were not able to accomplish a definite relation between RT on the neck and increased 
risk of stroke.11 
The underlying pathogenetic mechanism in RT-related vascular changes is partly 
different from classical atherosclerosis.12 Whereas classical atherosclerosis is merely 
a disease of the intimal layer predominated by inflammation and lipid storage; RT-
related vascular changes affect the 3 arterial layers (i.e. the intima, the media and the 
adventitia). On the one hand, already existing atherosclerotic lesions seem to worsen 
by RT, but RT itself can also induce atherosclerotic changes in atherosclerotic-naive, 
young patients. Histological examination showed endothelial damage in an early 
post-RT stage.13 In the chronic phase, this probably leads to a cascade of inflammatory 
reactions that result in the proliferation of the endothelial (i.e. intima) layer, fibrosis 
of the medial layer, and obliteration of the vasa vasorum in the adventitial layer. The 
combination of these changes will eventually lead to narrowing of the arterial lumen. 
Correspondingly, thickening of the inner wall, expressed as the intima-media thickness 
(IMT), seems to be an independent predictor of cerebrovascular disease.14-16 RT could 
lead to enhancement of the IMT progression which in turn can result in carotid artery 
stenosis and consequently to ischemic cerebrovascular disease. Until now, the real 
impact of RT on IMT progression after neck irradiation is unknown.
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Duplex examination of the cerebropetal arteries is performed in patients with a 
transient ischemic attack or ischemic stroke. In case of a symptomatic stenosis of 
the ICA of more than 50-70%, it is advised to confirm this with MR-angiography or 
a conventional angiography. Patients who have undergone RT often show occlusive 
carotid disease at different locations compared to patients with classic age-related 
atherosclerosis. In general, these occlusive lesions are more extensive after RT17-
19 and are often found outside the bifurcation: in the common carotid artery, the 
distal internal carotid artery, or the external carotid artery, which corresponds to 
the full radiation area.4 The best treatment of RT-related symptomatic ICA stenosis 
is unknown. In line with the extensive studies that have been performed in patients 
with a stenosis based on atherosclerosis, a CEA is advised in case of a symptomatic 
ICA stenosis with a luminal reduction of more than 70%.20 However, the neck area of 
these patients is also called “hostile neck” because of the fibrotic abnormalities and 
the disrupted anatomy (figure 2).21 Therefore CEA can be a technically difficult and 
thus a risk-bearing procedure. In fact, in the extensive North American Symptomatic 
Carotid Endarterectomy Trial (NASCET), these patients were excluded from the study 
because of the high surgical risk.20 CAS could offer a good alternative for these “hostile 
neck” patients. This technique consists of a percutaneous balloon dilatation followed 
by stent placement. The value of this intervention compared to CEA in patients with 
classic atherosclerosis is the topic in randomized studies at present.22 Endovascular 
treatment in patients who have undergone RT on the neck has not been studied 
sufficiently to establish the utility in this specific patient population. 
To prevent is better than to heal also applies for irradiated patients; from this view, 
preventive measurement should become available for patients who will undergo 
irradiation on large arteries, like the carotid and coronary arteries. Until now, no 
study has focused on prevention of RT-related vascular changes. The best advise 
for the treating physicians is to consider risk reducing strategies since additional 
cerebrovascular risk factors contribute to RT induced vasculopathy.
Aims and outline of the thesis
General aims of the present thesis were (I) to evaluate the long-term risk of radiation 
induced vasculopathy and (ischemic) cerebrovascular disease in cancer survivors 
who have been treated with radiotherapy on the neck, (II) to assess the outcome of 
endovascular treatment of radiation induced carotid stenosis, and (III) to initiate a 
randomized, multicenter trial on the prevention of radiation related vasculopathy. 
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For this purpose we examined the risk of ischemic stroke in head and neck cancer 
patients who received irradiation on the neck before the age of 60 years. 
The incidence was compared with stroke rates of the general population, together 
with the cumulative risk of stroke (chapter 2.1).
Since we were interested in the occurrence of cerebrovascular disease as a consequence 
of irradiation in other cancer survivors; we performed treatment specific analysis in the 
Late Effects Breast Cancer Study (chapter 2.2) and in Hodgkin’s lymphoma survivors 
(chapter 2.3). Treatment specific risk factors of radiation fields were studied, as well as 
the etiology of ischemic cerebrovascular disease.
To study the real impact of radiotherapy on the carotid artery we performed a cross-
sectional study in patients irradiated unilaterally on the neck. A duplex ultrasonographic 
comparison of the intima-media thickness of the irradiated versus the unirradiated 
carotid artery was performed (chapter 3.1).
To evaluate the possibility of endovascular treatment of radiation induced carotid 
stenosis we assessed the outcome in terms of the occurrence of cerebrovascular 
disease and restenosis after stenting (chapter 4.1).
In an attempt to prevent radiation induced vasculopathy, we initiated a randomized, 
multicenter trial. The effect of atorvastatin, a cholesterol-lowering drug on reducing 
the intima-media thickness progression is evaluated within patients who will receive 
radiotherapy on the neck region (chapter 5.1).  
Figure 2.  Extensive fibrotic abnormalities and teleangiectasia in the neck. 
The neck abnormalities are usually referred to as “hostile neck”.
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Abstract
Purpose
To estimate the risk of ischemic stroke in patients irradiated for head and neck 
tumors.
Patients and methods
The incidence of ischemic stroke was determined in 367 patients with head and neck 
tumors (162 larynx carcinoma, 114 pleomorphic adenoma, and 91 parotid carcinoma) 
who had been treated with local radiotherapy (RT) at an age younger than 60 years. 
Relative risk (RR) of ischemic stroke was determined by comparison with population 
rates from a stroke-inciden ce register, adjusted for sex and age. Other risk factors for 
stroke (hypertension, smoking, hypercholesterolemia, diabetes mellitus (DM)) were 
registered. The median follow-up time after RT was 7.7 years (3,011 person-years of 
follow-up).
Results
Fourteen cases of stroke occurred (expected 2.5; RR 5.6; 95% confidence interval (CI) 
3.1-9.4): eight in patients with laryngeal carcinoma (expected 1.56; RR 5.1; 95% CI 2.2-
10.1), four in patients with pleomorphic adenoma patients (expected 0.71; RR 5.7; 
95% CI 1.5-14.5), and two in parotid carcinoma patients (expected 0.24; RR 8.5; 95% 
CI 1.0-30.6). Five of six strokes in patients irradiated for a parotid tumor occurred at 
the ipsilateral side. Analysis of other risk factors for cerebrovascular disease showed 
hypertension and DM to cause an increase of the RR after RT. After more than 10 years’ 
follow-up, the RR was 10.1 (95% CI 4.4-20.0). The 15-year cumulative risk of stroke after 
RT on the neck was 12.0% (95% CI 6.5%-21.4%).
Conclusion
This is the first study to demonstrate an increased risk of stroke after RT on the neck. 
During medical follow-up, preventive measures should be taken to reduce the impact 
of the risk factors for cerebrovascular disease, to decrease stroke in these patients. 
Increased risk of ischemic stroke after radiotherapy on the neck
23
Introduction
Radiotherapy (RT) is a common curative treatment modality for head and neck 
malignancies and may serve as adjuvant therapy in post-operative conditions for some 
benign tumors. Successful treatment increases survival but also puts the patient at risk 
for radiation-related side effects. In this respect, vascular side effects are serious and 
may be life threatening. Already in 1899 Gassmann reported effects of RT on vascular 
tissue.1 Thereafter several studies described radiation-induced atheromatous disease 
of major arteries in a variety of locations.2-4 Similar changes have also been reported 
involving the carotid artery after neck irradiation.5-9
Long-term vascular complications are usually contributed to accelerated 
atherosclerosis of the irradiated vessels, which increases the risk of vascular stenosis 
and thromboembolism. The main sequelae of carotid atherosclerosis include transient 
ischemic attacks, ischemic strokes and amaurosis fugax.10  The reported intervals between 
irradiation and first symptoms range from 6 months to more than 20 years.10,11 
Case reports combined with histopathological studies suggest a possible relationship 
between RT and occurrence of stroke.6-8 However, the extent of a possible increase 
of risk due to RT can not be assessed from reports published so far. Moreover, most 
reported patients had also received surgical therapy for their head and neck tumors, 
which might have contributed to the carotid artery pathology.12 In only one study was 
the incidence of stroke in patients irradiated on the neck compared with the expected 
incidence in a population of similar age and sex.13 No significant increase of the risk of 
stroke after previous RT on the neck was found. However, inclusion of operated, not-
operated patients, and elderly patients makes those study results hard to interpret. 
With this background, we investigated a consecutive series of patients protocollary 
treated for head and neck tumors at relatively young age (< 60 years), to assess the 
relative risk (RR) of stroke after irradiation on the neck.
  
Patients and Methods
Patients
The study group consisted of two categories of patients; those with laryngeal carcinoma 
primarily treated with RT, i.e. T1 and T2 carcinomas, and patients with parotid gland 
tumors i.e. pleomorphic adenoma and parotid carcinoma. This patient selection was 
made in order to constitute a homogeneous study population with approximately 
the same treatment protocol, and with an expected long term survival and follow-
up. Patients with T3 and T4 laryngeal carcinomas and patients with oro-pharyngeal 
carcinomas were excluded because of their limited survival time, and because of 
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operative intervention in the carotid area . Patients with laryngeal carcinoma received 
RT with a curative intent. Patients with pleomorphic adenomas underwent a superficial 
parotidectomy, and postoperative RT was indicated by tumor spill and/or incomplete 
microscopic clearance. Parotid carcinomas were surgically removed by performing a 
total (conservative) parotidectomy followed by RT.  
A retrospective cohort study was performed of patients treated between January 1977 
and January 1998 at the Netherlands Cancer Institute/ Antoni van Leeuwenhoekhuis. 
Patients older than 60 years were excluded in order to constitute a relatively young study 
population with low risk of cerebrovascular disease. A minimal follow-up time of 0.5 year 
was required in order to exclude acute complications of treatment, which might harbor 
a different pathogenesis.8 During the period  from January 1, 1977, January 1, 1998, 
383 patients fulfilled the inclusion criteria. Records were untraceable for 16 patients. 
Thus, this study was restricted to the 367 patients who received RT on the neck.
From each patient chart, the following data were collected: sex, age, primary tumor, 
timing of RT, RT dosage and fraction size, risk factors of cerebrovascular disease, interval 
from RT to stroke occurrence, interval from start of RT to last visit during follow-up, and 
date and cause of death. The recorded risk factors included smoking, hypertension, 
diabetes mellitus (DM) and hypercholesterolemia. Hypertension was defined as either 
treatment for high blood pressure or a blood pressure that twice exceeded the limit 
of  95 mm Hg diastolic blood pressure. Smoking was scored positive when the patient 
was currently smoking or had quit smoking less than 2 years before last follow-up. Each 
patient treated for DM was scored as positive. The cut-off value for hypercholesterolemia 
was 6.5 mmol/L. Criteria for cerebrovascular symptoms were a fixed neurological 
deficit lasting for more than 24 hours (subarachnoidal and intracerebral haemorrhage, 
transient ischemic attack, and amaurosis fugax were excluded). In all cases, the clinical 
diagnosis was based on a neurological examination and in most cases it was confirmed 
by a computed tomography or magnetic resonance imaging scan.
In case of incomplete follow-up data in the patient record, the general practitioner 
was requested to provide relevant data by a questionnaire that elicited risk factors and 
history of cerebrovascular disease. 
Radiotherapy 
Patients with laryngeal carcinoma were irradiated with a total dose of 60 to 66 Gy 
delivered in fractions of 2 to 2.4 Gy (five fractions per week). Two lateral fields, 5 x 5 
cm in size, were treated each day. Wedges and a plastic shell were used to immobilize 
patients. Linear accelerators with 8-MV and 4-MV photons replaced the cobalt-60 
machine in the later years. The RT portal included both carotid areas. The estimated 
dose of RT at the carotid artery level was 95% to 100% of the administered total dose. 
The dose of RT in patients with pleomorphic adenoma was 50 Gy in fractions of 2 Gy, 
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and the post-operative treatment for patients with parotid carcinoma consisted of 
60 Gy in fractions of 2 Gy (five fractions per week). The radiation technique used was 
two lateral oblique-wedged fields with 4- to 8-MV photons encompassing the parotid 
gland area and upper neck nodal regions in patients with malignant tumors. Typically 
these fields included the ipsilateral carotid artery over an average length of 10 cm. The 
estimated dose at the carotid level was 95% to 100% of the administered dose. 
Statistical Analysis
A person-time analysis was carried out in which the incidence of ischemic stroke in the 
study population was compared with the incidence in the general population. In this 
type of analysis, accumulation of person-time at risk for stroke began at start of first 
treatment with RT, and ended at date of diagnosis of stroke, date of death, or date of 
most recent medical follow-up examination, whichever came first. 
Expected numbers of ischemic stroke were computed by multiplying the accumulated 
age- and sex-specific person-years with corresponding age- and sex-specific incidence 
rates from the Oxfordshire Community Stroke Project (OCSP).14 This British study was 
used because it covers much more detailed age- and sex-specific incidence rates than 
the smaller and less detailed Dutch Tilburg study, which is the only available one in the 
Netherlands.15 From a thorough inspection of both studies on differences in incidence rates, 
we learned that ischemic stroke rates appeared quite comparable in the two countries. 
Thus, with survival experience (person-years) of the population of the irradiated patients 
taken into account, RRs were calculated as observed/expected ratios overall, and for 
separate categories of primary tumor, sex, follow-up interval, and several risk factors. 
Confidence limits of the ratios were obtained with the use of the Poisson distribution 
of observed cases.16 The results were also used to calculate the absolute excess risk, by 
subtracting the expected number of cases from the number of observed, multiplying 
by 1,000, and finally divided by person-years at risk. This risk, which estimates the 
excess number of strokes per 1,000 patients per year, is the most appropriate measure 
to judge which factors contribute most to the excess risk. 
Cumulative proportions of stroke incidence were estimated as a function of time since 
initial treatment. A life-table analysis was carried out according to the product-limit 
method first described by Kaplan and Meier.17 
Results
The characteristics of  the 367 patients according to the type of tumor are described in 
table 1. Thirty patients with laryngeal carcinoma underwent laryngectomy, including 
neck dissection, for recurrent disease.
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Table 1. Patients characteristics
Overall Larynx 
carcinoma
Pleomorphic 
adenoma
Parotid 
carcinoma
Number of patients 367 162 114 91
Male 224 134 42 48
Female 143 28 72 43
Person years 3011 1270 1114 626
Male 1755 1108 358 288
Female 1256 162 756 338
Median age at treatment (years) 49.3 53.7 41.5 43.0
Median follow-up (years) 7.8 7.6 9.7 6.0
Range follow-up (years) 0.5-22.6 0.5-22.4 0.7-22.6 0.6-21.4
Dose of RT (Gy) 50-66 60-66 50 60
Overall 14 out of 367 patients experienced a first ischemic stroke after RT. The overall 
risk of stroke after RT was significantly increased compared with the general population 
(RR 5.6; 95% CI 3.1-9.4). The median age at stroke was 62.7 years. The median interval 
from RT to occurrence of stroke was 10.9 years (range 1.3 to 21.0 years). The absolute 
excess risk (AER), which estimates the excess number of strokes per 1,000 patients per 
year, amounted to 3.8 in the whole group. 
Table 2 shows the number of stroke cases, expected numbers, RR and AER for the 
whole group and the separate groups. 
Table 2. Observed and expected cases, relative and absolute excess risk of ischemic stroke after RT
Overall Larynx-
carcinoma
Pleomorphic 
adenoma
Parotid 
carcinoma
Observed numbers of stroke 14 8 4 2
Expected strokes 2.50 1.56 0.71 0.24
Relative Risk 5.6 5.1 5.7 8.5
95% Confidence Interval 3.1-9.4 2.2-10.1 1.5-14.5 1.0-30.6
Median age at stroke (years) 62.7 62.7 63.0 58.2
Median interval treatment to stroke (years) 10.9 7.1 13.6 8.5
Range treatment to stroke (years) 1.3-21.0 1.3-13.4 10.9-21.0 2.1-14.9
Absolute excess risk (per 1,000/year) 3.8 5.1 3.0 2.8
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Table 3 lists the stroke characteristics and the outcome of the patients after the 
occurrence of stroke. The two strokes observed in the group of patients with parotid 
carcinoma were both on the irradiated side. In the group of patients with pleomorphic 
adenoma, one out of four stroke patients experienced a stroke on the contralateral, 
unirradiated side. One out of eight patients with stroke in the group of laryngeal 
carcinoma had been treated 5 years after irradiation with a total laryngectomy and 
neck dissection for a local recurrence. The interval between the operation and the 
ischemic stroke was 6 years. In all 14 cases, the infarction area was in the carotid 
artery territory. Angiography revealed carotid artery stenosis or occlusion localized 
to the irradiated level, typically without signs of atherosclerosis at the non-irradiated 
segments (figure 1).
 
Table 3. Patient case histories and stroke characteristics
Pt Sex Age at 
stroke 
(years)
Tumor Side of RT Infarction Territory Outcome 
1 F 62 Larynx carcinoma Both Right and Left 
hemisphere
Good
2 F 66 Pleomorphic 
adenoma
Right Right hemisphere Good
3 M 72 Larynx carcinoma Both Left hemisphere Good
4 F 53 Pleomorphic 
adenoma
Right Right hemisphere Good
5 F 70 Larynx carcinoma Both Right hemisphere Moderately disabled
6 M 76 Larynx carcinoma Both Right hemisphere Severely disabled
7 M 65 Larynx carcinoma Both Left hemisphere Mildly disabled
8 F 61 Pleomorphic 
adenoma
Right Right hemisphere Good
9 M 50 Larynx carcinoma Both Left hemisphere Mildly disabled
10 F 55 Larynx carcinoma Both Right hemisphere Mildly disabled
11 M 63 Larynx carcinoma Both Left hemisphere Mildly disabled
12 M 72 Pleomorphic 
adenoma
Left Right hemisphere Good
13 F 51 Parotid carcinoma Right Right hemisphere Mildly disabled
14 F 65 Parotid carcinoma Left Left hemisphere Dead
In table 4 the distribution of other risk factors for cerebrovascular disease is shown. 
Table 5 lists the RR and AER of stroke according to the risk profile. The RR was higher 
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in patients with hypertension (RR 12.5; 95% CI 4.6-27.2) than in patients without 
hypertension (RR 4.3; 95% CI 1.8-8.4), although the difference was not statistically 
significant. The same tendency was seen in patients with DM. Smokers and nonsmokers 
had approximately similar RRs of stroke. 
Figure 1.  Angiogram of the right carotid artery demonstrates (at the level of C4-C5) occlusion of the internal 
carotid artery about 2 cm distal to the bifurcation, but with a normal aspect of the proximal carotid artery 
(patient no. 10).
Table 4. Distribution of other risk factors for stroke
Risk factor Overall (%)
Hypertension Yes 15.5
No 78.2
Unknown 6.3
Diabetes Mellitus Yes 3.8
No 85.0
Unknown 11.2
Smoking Yes 43.6
No 44.1
Unknown 12.3
According to table 5, we found that patients with hypertension or DM who were 
irradiated on the neck had an AER of stroke of 11.6 and 17.7 per 1,000 patients per 
year, respectively, compared to the general population.
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Table 5. Analysis of other risk factors
Risk factor Observed 
strokes
Expected
strokes
RR 95% CI AER /1,000/yr*
Overall 14 2.50 5.6  3.1-9.4 3.8
Hypertension No 8 1.87 4.3 1.8-8.4 2.6
Yes 6 0.48 12.5 4.6-27.2 11.6
Diabetes mellitus No 12 2.07 5.8 3.0-10.1
Yes 2 0.17 12.1 1.5-43.5 17.7
Smoker No 8 1.26 6.4 2.7-12.5 4.5
Yes 6 1.04 5.7 2.1-12.5 4.3
* Absolute excess risk (AER) per 1,000 patients per year
An analysis by duration of follow-up revealed increased RR and AER during follow-up 
time (table 6). After more than 10 years’ follow-up, the RR was 10.1 (95% CI 4.4-20.0) 
and the AER was 14.0 per 1,000 patients per year. In the group of patients younger 
than 50 years during RT, the RR was 9.8 (95% CI 3.2-22.9) compared with 4.5 (95% CI 
2.1-8.6) in the group of patients older than 50 years during RT.
 
Table 6. Relative and absolute excess risks of stroke according to follow-up interval, age at radiotherapy 
and gender
Person-
years
Observed
cases
Expected
cases
RR 95% CI AER/1,000/yr *
Follow-up time
0-9 years 2,313 6 1.63 3.7 1.3-8.0 1.9
> 10 years 514 8 0.79 10.1 4.4-20.0 14.0
Age at RT
< 50 years 1,659 5 0.51 9.8 3.2-22.9 2.7
> 50 years 1,351 9 1.99 4.5 2.1-8.6 5.2
Gender
Male 1,755 8 1.91 4.2 1.8-8.2 3.5
Female 1,256 6 0.59 10.2 3.7-22.2 4.3
* Absolute excess risk (AER) per 1,000 patients per year
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Figure 2 shows the cumulative risk of stroke by follow-up time. After 15 years of follow-
up, the cumulative risk  amounted to 12.0% (95% CI  6.5%-21.4%).
Figure 2. Cumulative risk of stroke after RT on the neck
Discussion 
Several case reports and histopathological studies suggest a relation between RT and 
large vessel disease.2,3,5,10,18,19 To the best of our knowledge, our study is the first to 
show a significant increased risk of ischemic stroke in an irradiated patient population 
with head and neck tumors. The risk of stroke after RT on the neck has already been 
investigated by Elerding et al.,13 but they were not able to demonstrate a significant 
correlation between RT and stroke. In comparison with Elerding et al., we studied a 
more homogenous group of patients who were treated with approximately the same 
dose of RT and who had a relatively favorable prognosis for vascular events because 
of  their age, i.e., below 60 years at RT. We excluded patients with T3 and T4 laryngeal 
carcinomas, oropharyngeal carcinomas and lymphomas because their treatment 
protocol consist of RT in combination with chemotherapy and/or operative intervention 
in the carotid area. These procedures may be associated with an increased incidence of 
vascular disease,12,19,20 which could make the results hard to interpret. 
Recently, a meta-analysis on the long-term survival of patients irradiated for early 
breast cancer showed a significantly increased vascular mortality after the first decade 
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following RT.21 This study underlines the long term effect of RT on the development of 
radiation-induced vascular disease. In our study we also found a significantly increased 
risk of ischemic stroke after more than ten years of follow-up.
The assumed pathogenesis of radiation-induced vascular disease is an acceleration 
of the atherosclerotic process probably due to endothelial cell damage, fibrosis of the 
intima-media layer and development of atheromatous plaques, which is increased by 
occlusive changes in the vasa vasorum leading to ischemia of the arterial wall. This 
contributes to additional damage of the carotid artery.5,18 The risk of ischemic stroke is 
presumably related to the increase of the intima-media thickness and narrowing of the 
vascular lumen. This is reflected in the high excess number of strokes of 14.0 per 1,000 
patients per year after 10 years following RT on the large carotid artery compared to 
a 1.9 excess number of strokes when the interval from RT is shorter than 10 years. This 
seems also reflected in the more exponential curve of the actuarial risk of stroke from 
10 years following RT (figure 2). Besides, an increased incidence of stroke in the control 
group of the same age probably contributes to the exponential course of the curve at 
advanced age. 
Five out of six strokes occurring at the ipsilateral side of the irradiated parotid tumors 
corroborates the hypothesis that radiation-induced atherosclerosis of the carotid 
artery is the pathogenic factor. 
Age at RT may be of importance. Hancock et al.22 observed a highly significant increased 
risk of cardiovascular complications after mediastinal RT for Hodgkin’s disease in 
patients treated before they were 20 years old compared with those treated when 
they were older than 50 years. In the present study, the RR of stroke was 9.8 in patients 
treated before 50 years old compared to 4.5 in older patients; the difference was not 
significant.
The applied radiation dose in the present study varied between 50 Gy and 66 Gy. The 
minimal dose for RT-damage of the cervical arteries is assumed to be 40 Gy.23 Chung 
et al.,11 evaluating the degree of carotid stenosis on post-radiation MR scans, found no 
dose-effect relationship when RT dose was increased to 60 Gy.
The risk factor hypertension increased the risk (RR 12.5) of stroke after RT. No difference 
in the RR of stroke was observed between smokers and nonsmokers. However, this 
finding should be interpreted with caution, because registration of smoking habits in 
a retrospective analysis is probably inaccurate. The statement that stroke in patients 
with head and neck tumors should be ascribed to their lifestyle, including excessive 
smoking, does not hold true for patients with a parotid tumor. Moreover, a significant 
proportion of the patients with laryngeal carcinoma stopped smoking at the diagnosis 
of cancer. In view of the median interval of 7 years between RT and occurrence of 
stroke in these patients, and the observed similar RR of stroke in patients with laryngeal 
carcinoma and parotid tumor, smoking habits in our population of patients presumably 
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did not play a significant role in the observed increased risk of stroke compared with 
the matched normal populations.
Hypercholesterolemia may also play a role in the development of stenosis after RT. 
Silverberg et al.24 found hypercholesterolemia to be a contributory risk factor for 
radiation-accelerated atherosclerosis, as was also demonstrated in animal studies.25,26 
In our population, only a few patients (22.6%) were screened for cholesterol-levels, 
which made data inconclusive.  
As treatment for malignancies becomes more effective, more patients will survive and 
long-term cerebrovascular disease will become more prominent. This highlights the 
need for  long-term follow-up after curative treatment for head and neck cancer. During 
follow-up more attention should be paid to reduction of risk factors for atherosclerosis 
in patients who received RT on the neck. Routine performance of  carotid non-invasive 
studies, like ultrasound may be worthwhile. In this respect, in case of amaurosis fugax, 
transient ischemic attack, or stroke, the patient needs neurological evaluation to 
investigate possible therapeutic interventions. 
RT-induced carotid artery lesions, as seen on angiography can easily be differentiated 
from normal artherosclerotic lesions. The lesions appear to have a disproportionate 
involvement of the distal common carotid artery, according to the irradiated area, 
are usually long, and are not confined to the bifurcation.27 In addition, they are often 
associated with occlusion of other cervical arteries within the radiated portal.28 
Therapeutic options consist of percutaneous transluminal angioplasty (PTA), carotid 
endarteriectomy and, bypass surgery. However, these techniques remain difficult 
because of arterial, periarterial  and cutaneous sclerosis. Complications are divers 
and included scar disruption, prosthetic infection, anastomotic breakdown, wound 
healing problems and restenosis.28 Reports about carotid artery repair after neck 
radiation include less than 100 patients and most have been isolated cases. Recently, 
Kashyap et al.,29 presented the results of two decades of follow-up of carotid artery 
repair in 24 patients. They concluded carotid surgery after neck radiation to be a safe 
and durable treatment. Furthermore, they found this intervention to guarantee the 
protection against neurologic events similar to the results obtained in endarterectomy 
in the absence of RT. Although surgery is an option for intervention, we would rather 
emphasize prevention of cerebrovascular disease after RT, which can be achieved in 
part by reduction of risk factors. The benefit of prophylactic antiplatelet therapy and 
the use of statins or angiotensin-converting-enzyme inhibitors remain uncertain in 
this matter. Indications for post-operative RT in case of incomplete surgical removal 
of pleomorphic adenoma and/or tumor spill should be re-evaluated and weighed 
against the increased risk of neurological complications.30 
Increased risk of ischemic stroke after radiotherapy on the neck
33
References
1.  Gassmann A. Zur histologie der roentgenulcera. Fortschr Geb Roentgenstr. 1899;2:199-
207.
2.   Butler MJ, Lane RH, Webster JH. Irradiation injury to large arteries. Br J Surg. 1980;67:341-
343.
3.  Pettersson F, Swedenborg J. Atherosclerotic occlusive disease after radiation for pelvic 
malignancies. Acta Chir Scand. 1990;156:367-371.
4.  Taylor PJ, Cooper GG, Sarkar TK. Upper-limb arterial disease in women treated for breast 
cancer. Br J Surg. 1995;82:1089-1091.
5.  Atkinson JL, Sundt TM, Jr., Dale AJ, Cascino TL, Nichols DA. Radiation-associated 
atheromatous disease of the cervical carotid artery: report of seven cases and review of the 
literature. Neurosurgery. 1989;24:171-178.
6.  Conomy JP, Kellermeyer RW. Delayed cerebrovascular consequences of therapeutic 
radiation. A clinicopathologic study of a stroke associated with radiation-related carotid 
arteriopathy. Cancer. 1975;36:1702-1708.
7.  Levinson SA, Close MB, Ehrenfeld WK, Stoney RJ. Carotid artery occlusive disease following 
external cervical irradiation. Arch Surg. 1973;107:395-397.
8.  McCready RA, Hyde GL, Bivins BA, Mattingly SS, Griffen WO, Jr. Radiation-induced arterial 
injuries. Surgery. 1983;93:306-312.
9.  Osgood CP, Karunaratne ER, Sandler R, Vandevander DJ. Carotid occlusion in a 27-year-old 
man: a case report. Neurosurgery. 1986;18:459-460.
10.  Murros KE, Toole JF. The effect of radiation on carotid arteries. A review article. Arch Neurol. 
1989;46:449-455.
11.  Chung TS, Yousem DM, Lexa FJ, Markiewicz DA. MRI of carotid angiopathy after therapeutic 
radiation. J Comput Assist Tomogr. 1994;18:533-538.
12.  Nosan DK, Gomez CR, Maves MD. Perioperative stroke in patients undergoing head and 
neck surgery. Ann Otol Rhinol Laryngol. 1993;102:717-723.
13.  Elerding SC, Fernandez RN, Grotta JC, Lindberg RD, Causay LC, McMurtrey MJ. Carotid artery 
disease following external cervical irradiation. Ann Surg. 1981;194:609-615.
14.  Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. A prospective study of acute 
cerebrovascular disease in the community: the Oxfordshire Community Stroke 
Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral 
infarction, primary intracerebral and subarachnoid haemorrhage. J Neurol Neurosurg 
Psychiatry. 1990;53:16-22.
15.  Herman B, Leyten AC, van Luijk JH, Frenken CW, Op de Coul AA, Schulte BP. Epidemiology 
of stroke in Tilburg, the Netherlands. The population-based stroke incidence register: 2. 
Incidence, initial clinical picture and medical care, and three-week case fatality. Stroke. 
1982;13:629-634.
Chapter 2.1
34
16. Pearson ES, Hartley HO. Biometrika Tables for Statisticians. Biometrica trust; 1976.
17.  Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J AM Stat 
Assoc. 1958;53:457-481.
18.  Fonkalsrud EW, Sanchez M, Zerubavel R, Mahoney A. Serial changes in arterial structure 
following radiation therapy. Surg Gynecol Obstet. 1977;145:395-400.
19.  Moritz MW, Higgins RF, Jacobs JR. Duplex imaging and incidence of carotid radiation injury 
after high-dose radiotherapy for tumors of the head and neck. Arch Surg. 1990;125:1181-
1183.
20.  Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term 
survivors of metastatic testicular cancer. J Clin Oncol. 2000;18:1725-1732.
21.  Favourable and unfavourable effects on long-term survival of radiotherapy for early breast 
cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative 
Group. Lancet. 2000;355:1757-1770.
22.  Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after 
treatment of Hodgkin’s disease. JAMA. 1993;270:1949-1955.
23.  Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. 
Medicine (Baltimore). 1985;64:16-35.
24.  Silverberg GD, Britt RH, Goffinet DR. Radiation-induced carotid artery disease. Cancer. 
1978;41:130-137.
25.  Gold H. Production of arteriosclerosis in the rat. Effect of x-ray and a high-fat diet. Arch 
Pathol. 1961;71:268-273.
26.  Lamberts, HB, de Boer W. Contributions to the study of immediate and early x-ray reactions 
with regard to chemo-protection. VII. X-ray-induced atheromatous lesions in the arterial 
wall of hypercholesterolaemic rabbits. Int J Radiat Biol. 1963;6:343-350.
27.   Loftus CM, Biller J, Hart MN, Cornell SH, Hiratzka LF. Management of radiation-induced 
accelerated carotid atherosclerosis. Arch Neurol. 1987;44:711-714.
28.  Melliere D, Becquemin JP, Berrahal D, Desgranges P, Cavillon A. Management of radiation-
induced occlusive arterial disease: a reassessment. J Cardiovasc Surg (Torino). 1997;38:261-
269.
29.  Kashyap VS, Moore WS, Quinones-Baldrich WJ. Carotid artery repair for radiation-associated 
atherosclerosis is a safe and durable procedure. J Vasc Surg. 1999;29:90-96.
30.  Leverstein H, van der Wal JE, Tiwari RM, van dW, I, Snow GB. Surgical management of 246 
previously untreated pleomorphic adenomas of the parotid gland. Br J Surg. 1997;84:399-
403.


Published as: 
Lucille D.A. Dorresteijn*, Maartje J. Hooning*, Berthe M.P. Aleman, Arnoud C. Kappelle,  
Jan G.M. Klijn, Willem Boogerd, Flora E. van Leeuwen
*Both authors contributed equally to this work. 
 
J Clin Oncol. 2006; 24: 5388-94. 
Decreased risk of stroke among  
10-year survivors of breast cancer
Chapter
2.2
Chapter 2.2
38
Abstract
Purpose
To assess treatment-specific risk of cerebrovascular events in early breast cancer (BC) 
patients, accounting for cerebrovascular risk factors. 
Patients and methods
We studied the incidence of cerebrovascular disease (CVA; stroke and transient 
ischemic attack (TIA)) in 10-year survivors of early BC (n = 4414) treated from 1970 to 
1986. Follow-up was 96% complete until January 2000. Treatment-specific incidence 
of CVA was evaluated by standardized incidence ratios (SIRs) based on comparison 
with general population rates and by Cox proportional hazards regression. 
Results
After a median follow-up of 18 years, 164 strokes and 109 TIAs were observed, resulting 
in decreased SIRs of 0.8 (95% confidence interval (CI) 0.6-0.9) for stroke and 0.8 (95% 
CI 0.7-1.0) for TIA. Significantly increased risk of stroke was found in women who had 
received hormonal treatment (HT; tamoxifen), and in women who had hypertension or 
hypercholesterolemia, with hazard ratios (HRs) of 1.9, 2.1, and 1.6, respectively. Patients 
irradiated on the supraclavicular area and/or internal mammary chain (IMC) did not 
experience a higher risk of stroke (HR 1.0; 95% CI  0.7-1.6) or TIA (HR 1.4; 95% CI 0.9-2.5) 
compared with patients who did not receive radiotherapy or who were irradiated on 
fields other than supraclavicular area or IMC. 
Conclusions
Long-term survivors of BC do not experience an increased risk of cerebrovascular 
events compared with the general population. HT is associated with an increased risk 
of stroke. Radiation fields including the carotid artery do not seem to increase the risk 
of stroke compared with other fields. 
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Introduction 
The prognosis of patients with early breast cancer (BC) has significantly improved 
over the past decades as a result of earlier diagnosis and the use of multimodality 
treatment. Meta-analyses of randomized clinical trials by the Early Breast Cancer 
Trialists’ Collaborative Group have shown an important reduction in local recurrence 
rate and in BC mortality as a result of the application of postoperative adjuvant 
radiotherapy (RT)1-3 and adjuvant systemic therapy.4 However, adjuvant RT has also 
been associated with increased risks of cardiovascular morbidity and second primary 
cancers.5-7 Exposure to chemotherapy or hormonal therapy (HT) may even further 
increase the risk of cardiovascular disease.8,9 
In BC patients treated with adjuvant RT, the coronary arteries, brachiocephalic trunk, 
subclavian artery, and common carotid arteries (CCAs) may be exposed, depending 
on the fields applied. As a result, BC patients are potentially at risk for late vascular 
sequelae of RT.10-14 So far, nearly all studies on vascular sequelae after BC irradiation 
have focused on the risk of cardiac disease. RT-related stroke is mediated by accelerated 
atherosclerosis that can result in enhanced thromboembolism and stenosis of the 
area of the carotid artery within the RT portal.15,16 Head and neck cancer patients and 
survivors of Hodgkin’s lymphoma treated with local RT on the neck experience an 
increased risk of stroke during long-term follow-up.17-19 In case of irradiation on the 
supraclavicular lymph nodes, the proximal part of the CCA is located within the RT 
portal. Therefore, we hypothesize that BC patients irradiated at the supraclavicular 
lymph nodes are subject to an increased risk of stroke. 
Until now, no study has reported on the incidence of ischemic stroke in relation 
to specific radiation regimens for BC. Therefore, we examined the incidence of 
cerebrovascular accident (CVA) in the Dutch Late Effects Breast Cancer cohort. Unique 
features of this study include near-complete and long-term follow-up (median 18 
years), the assessment of cerebrovascular risk according to radiation field, and the 
incorporation of cerebrovascular risk factors into the analysis. 
 
Patients and methods
Data collection procedures
The Late Effects Breast Cancer cohort consists of 7425 1-year survivors, younger than 
71 years of age at diagnosis, treated for stage I, II, or IIIA  female BC in the period from 
1970 to 1986 in the Netherlands Cancer Institute or the Erasmus MC, Daniel den 
Hoed Cancer Center. A detailed description of data collection procedures has been 
published previously.20  In brief, all patients were identified through the hospital-based 
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cancer registries of the two centers. From the registries and the oncologic records, we 
collected the following information: date of BC diagnosis, tumor histology, axillary 
lymph node involvement, dates and treatment modalities of primary BC and of 
recurrent disease (i.e. type of surgery, radiation fields, cytostatic agents, and HT), dates 
of stroke and transient ischemic attack (TIA), cerebrovascular risk factors, date of most 
recent medical information or date of death and primary cause of death. Risk factors 
(such as smoking, hypertension, diabetes mellitus (DM), and hypercholesterolemia) 
were recorded both at the date of diagnosis of BC and at the end of follow-up. Smoking 
was scored positive when the patient was currently smoking or had stopped smoking 
less than 1 year before. Hypertension, hypercholesterolemia and DM were scored as 
positive when stated in the medical information or when treated.
We restricted this study to patients who survived BC for at least 10 years (n = 4414) 
because the increase in risk of vascular events associated with RT seems to emerge 
after 10 or more years.2,5,15,16,18,20 For these patients, we updated information until 
at least January 1, 2000 on cerebrovascular diagnoses and risk factors by sending 
questionnaires to their general practitioners (GPs). In The Netherlands, nearly all 
residents have a GP who receives all medical correspondence from attending 
physicians. Forty-six patients were excluded from the cohort because their oncologic 
records did not contain information after 10 years since diagnosis and no additional 
information on vascular events could be obtained from their GPs. For the remaining 
4368 patients, we collected cerebrovascular data for 83% of the patients from both the 
medical record and the GP, and for the other 17% of patients, we collected data from 
the oncologic records only. Complete follow-up information was eventually available 
for 4259 patients (96%). For patients who died from a stroke, without prior evidence 
of a cerebrovascular event, the date of death was recorded as date of diagnosis of 
stroke. 
Treatment
During the 1970s, standard treatment for stage I, II, and IIIA BC was modified or radical 
mastectomy with or without RT. As of 1975, adjuvant systemic treatment was introduced 
for node-positive patients, including combination chemotherapy for premenopausal 
patients and, gradually from 1980 onwards, tamoxifen for postmenopausal patients. 
Standard adjuvant chemotherapy consisted of cyclophosphamide, methotrexate and 
fluorouracil during the whole study period. In 1980, breast-conserving therapy was 
introduced in both hospitals. The RT regimen depended on type of surgery and stage 
of disease. In both hospitals, irradiation of the ipsilateral internal mammary chain (IMC) 
field was common for patients with centrally or medially located tumors and/or axillary 
lymph node metastases. The dose in the IMC varied from 40 Gy in 15 fractions in 3 
weeks to 50 Gy in 25 fractions, using either photon beams or a mixture of photons and 
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electrons. In case of extensive axillary nodal metastases, the axilla and supraclavicular 
nodes were irradiated as well (50 Gy in 25 fractions). In case of irradiation of the IMC 
including the medial supraclavicular nodes or of the supraclavicular nodes, the dose 
in the proximal part of the CCA was estimated between 80 and 100% of the total dose 
(equivalent of 40 to 50 Gy in fractions of 2 Gy, figures 1a and 1b).
Figure 1. Schematic representation of the radiotherapy portal of the internal mammary chain field and the 
McWhirter (= supraclavicular + axillary) field in case of a) left-sided breast cancer and b) right-sided breast 
cancer. The estimated radiation dose at both the left and right common carotid artery is 40-50 Gy.
Statistical analysis
We compared the incidence of stroke and TIA in the study population with the incidence 
in the Dutch female population, taking into account the person-years of observation 
in the cohort (by age, calendar period, and follow-up interval). Incidence data of the 
Continuous Morbidity Registration–Nijmegen, derived from several GP practices 
from representative regions in The Netherlands, were used as reference rates.21 This 
registry has collected data on the incidence of vascular events (including TIA) for the 
period from 1972 to 2000, allowing for multiple separate diagnoses per person but 
recording only the first of a specific diagnosis per person. To assess treatment effects 
on stroke risk, we distinguished five mutually exclusive treatment categories based on 
all treatments received (table 1). Treatments administered in the last year of follow-
up were excluded from the analysis because we did not want to take into account all 
salvage treatments received for recurrent disease during the last period in life. We also 
analyzed the effects of specific RT fields.
Follow-up time was defined as the period from the date of first treatment until the 
date of most recent medical information (including date of death). Because the study 
was restricted to 10-year survivors, time at risk began 10 years after the start of first 
treatment and ended at date of diagnosis of stroke or TIA, date of death, or date of 
most recent medical information, whichever came first. Observed numbers were based 
on all first events of stroke and TIA occurring during time at risk (i.e. after at least 10 
years since first treatment); patients diagnosed with a cerebrovascular event before BC 
Figure 1a Figure 1b
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diagnosis or within 10 years since first treatment were excluded from the analysis. The 
standardized incidence ratios (SIRs) of the observed and expected numbers of stroke 
and TIA in the study population were determined, and the confidence intervals of the 
SIRs were calculated using exact Poisson probabilities of observed numbers.22 P-values 
for tests for trend were calculated according to standard methods. Absolute excess risk 
was calculated by subtracting the expected number of cerebrovascular events in our 
cohort from the number observed and dividing by person-years at risk (expressed per 
10,000 person-years). 
The Cox proportional hazards model was used to quantify the effects of different 
treatments on the risk of CVA, taking into account several covariates. To evaluate the 
independent effects of primary adjuvant treatment, we did a separate analysis where 
time at risk ended at date of treatment for recurrent disease. Cox models were fitted 
with the use of SPSS statistical software (SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics
The median age at BC diagnosis in the study population was 49 years, and 32% of 
patients were younger than 45 years at diagnosis (table 1). Median follow-up time was 
17.7 years, and 31% of the patients were followed for more than 20 years. Fifty-four 
percent of the patients were treated with a combination of RT and surgery, and 32% 
received RT and adjuvant chemotherapy and/or HT, the latter mostly for recurrent 
disease. Fifty-eight percent of patients received IMC RT, usually including the medial 
supraclavicular area, 50% were irradiated to the chest wall or breast region, and 24% 
were irradiated to the supraclavicular area.
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Table 1. Characteristics of 10-year survivors in the Dutch Late Effects BC Study 
Characteristic No. of BC patients %
No. of patients 4368 100
Hospital
NKI 2045 46.8
DDHK 2323 53.2
Age at BC diagnosis (years)
< 45 1379 31.6
45 - 54 1681 38.5
≥ 55 1308 29.9
Year of first treatment of BC
1970 - 75 1075 24.6
1976 - 80 1059 24.2
1981 - 86 2234 51.1
Axillary node involvement (at diagnosis)
Node negative 2557 58.5
Axillary node pos.,  subclav. neg. 1544 35.3
Subclav. pos. 164 3.8
Unknown 103 2.4
Laterality
Left 2229 51.0
Right 2097 48.0
Bilateral 42 1.0
Treatment category, primary + follow-up treatment
Surgery only 516 11.8
RT (+ surgery) 2362 54.1
RT + CT (+ surgery) 529 12.1
RT + HT (+ surgery) 438 10.0
RT + CT + HT (+ surgery) 448 10.3
Other/unknown 75 1.7
Radiation fields, primary + follow-up treatment*
IMC 2538 58.1
Chest wall 880 20.1
Breast 1319 30.2
Supraclavicular 1061 24.3
Axilla 1356 31.0
Radiation fields, primary + follow-up treatment**
IMC, no supraclavicular 1712 39.2
Supraclavicular, no IMC 227 5.2
IMC + supraclavicular 826 18.9
Other fields; but no IMC or supraclavicular 934 21.4
Unknown 60 1.4
Follow-up time (years)
10 - 14 1081 24.7
15 - 19 1917 43.9
 ≥ 20 1370 31.4
Abbreviations: BC, breast cancer; NKI, Netherlands Cancer Institute; DDHK, Erasmus MC, Daniel den Hoed 
Cancer Center; RT, radiotherapy; CT, chemotherapy; HT, hormonal therapy.
*Allowing more than one field per patient.
** Mutually exclusive treatment groups.
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Table 2 displays the information on cerebrovascular risk factors in the study population. 
We compared the distribution of hypertension, DM, and hypercholesterolemia by age 
categories in our study to the reference population from CMR–Nijmegen (table 3). 
Since this Registry had no data on smoking habits, we used figures from a nationwide 
survey held in 2000 for comparison.23 At the end of follow-up, the distribution of risk 
factors was very similar in our study group compared with the control population, 
with the exception of patients aged more than 75years, who had a significantly higher 
prevalence of hypertension (44% versus 34%, respectively; p < 0.001)
Table 2. Risk factors for stroke or TIA in 10-year survivors of the Dutch Late Effects BC Study
No. of patients %
Smoking:
Never 2136 48.9
Unknown at BC diagnosis, but not at end of follow-up 334 7.6
Smoking at BC diagnosis, but not anymore at end of follow-up 413 9.5
Smoking at BC diagnosis, unknown at end of follow-up 551 12.6
Smoking through the end of follow-up 426 9.8
Unknown 508 11.6
Hypertension:
No 3039 69.5
Diagnosed prior to BC diagnosis 444 10.2
Developed during follow-up 716 16.4
Unknown 169 3.9
Diabetes Mellitus:
No 3826 87.6
Yes 383 8.8
Unknown 159 3.6
Hypercholesterolemia:
No 3739 85.6
Yes 441 10.1
Unknown 188 4.3
History* of stroke/TIA:
No/ Unknown 4355 99.7
Yes     13 0.3
Abbreviations: BC, breast cancer; TIA, transient ischemic attack.
*Before BC diagnosis.
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Table 3. Distribution of risk factors (in %) by age categories
Smoking: Late effects BC study Dutch population
Age in 2000: % %
35 - 49 36 37
50 - 64 28 28
>= 65 15 15
Hypertension: Late effects BC study CMR Nijmegen
Age in 2000: % %
< 45   2   2
45 – 64 17 13
65 – 74 34 31
>= 75 44 34
Diabetes mellitus: Late effects BC study CMR Nijmegen
Age in 2000: % %
< 45 0.7 0.4
45 – 64   4   4
65 – 74 11 11
>= 75 12 15
Hypercholesterolemia: Late effects BC study CMR Nijmegen
Age in 2000: % %
< 45 0.2 0.4
45 – 64 12   7
65 – 74 17 16
>= 75 10   9
Abbreviations: BC, breast cancer; CMR, continuous morbidity registration.
Risk of CVA by age, follow-up and treatment regimen 
Overall, we observed 164 strokes and 109 TIAs (table 4), including 14 patients with 
both (TIA preceding stroke). In total, 51 patients died from a stroke. The median age 
at stroke diagnosis was 75.5 years after a median follow-up of 17.0 years; TIAs were 
diagnosed at a median age of 73.1 years after a median follow-up of 16.8 years.
With 217.6 strokes expected versus 164 seen, the risk of stroke was significantly 
decreased by 25% (SIR 0.75; 95% CI 0.64 - 0.88, table 4). Decreased risk of stroke was 
found for all age groups. For TIA, the risk was increased in patients younger than 45 
years old at BC diagnosis, with SIRs showing a consistent decline with older ages at 
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diagnosis of BC (p for trend < 0.0001; table 4). There was no trend over follow-up time 
for risk of stroke or TIA.
Risks of stroke and TIA did not differ between patients who were treated with 
surgery alone and those who received RT in combination with surgery. However, 
among patients who were treated with RT plus HT, we observed an elevated risk of 
stroke (SIR 1.31; 95% CI 0.87-1.88) compared with the general population, whereas 
risk of TIA was significantly increased in patients treated with RT plus chemotherapy 
(SIR 2.90; 95% CI 1.4-5.19).
Risk of CVA by RT field: Cox model analysis
Patients irradiated on the supraclavicular and/or IMC fields did not experience a higher 
risk of stroke or TIA compared with patients irradiated on fields other than supraclavicular 
or IMC fields or patients treated without RT  (table 5). Risk of stroke was most strongly 
associated with HT (HR 1.88), hypertension (HR 2.07), and hypercholesterolemia (HR 
1.64). For smoking and DM, we found nonsignificantly increased HRs of 1.37 and 1.33. 
In the analysis by primary treatment, where time at risk ended at date of treatment for 
recurrent disease, risk of stroke remained increased for adjuvant HT (HR 2.14; 95% CI 
0.62-7.32; table 5).
Discussion
This is the first long-term cohort study assessing the incidence of cerebrovascular 
events in early BC patients according to RT fields delivered. Overall, the risk of stroke 
was decreased by 25% in comparison with the general female population. Contrary 
to our expectation, risk of stroke was not increased in patients treated with adjuvant 
RT at the carotid arteries compared with non-irradiated patients. Of all treatment 
modalities, only HT was associated with an increased risk of stroke. Strongest risk 
factors were hypertension and hypercholesterolemia, but these factors did not modify 
the risk estimates for treatment. 
Data on risk of stroke in BC patients are scarce. Recently, Jagsi et al. found a non-
significantly elevated SIR of CVA (1.74; 95% CI 0.94-2.37) in patients with early BC after 
a median follow-up of 6.8 years.24 In the EBCTCG meta-analysis on effects of RT, the 
gain in BC survival from RT was partly offset by an increase of vascular mortality.2 A 
recent update3 showed that this excess vascular mortality mainly involved heart 
disease, whereas risk of stroke was not increased in irradiated versus non-irradiated 
patients. In a large population-based study (median follow-up, 5.4 years), Nilsson et al. 
found that BC patients had an overall relative risk (RR) of stroke of 1.12 (95% CI 1.07-
1.17) compared with the general population.25
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This increased risk was especially pronounced during the first year after diagnosis 
(RR 1.22; 95% CI 1.06-1.39). Possibly, the increase during the first year was caused by 
tumor-related coagulation disorders.26,27 The effect of specific treatment regimens 
could not be examined because of lack of information. Retrospective studies of head 
and neck tumor patients and survivors of Hodgkin’s lymphoma irradiated to the 
carotid region show a significantly increased risk of stroke. In BC patients, both left and 
right supraclavicular radiation portals include the ipsilateral CCA, with the left artery 
exposed over a slightly longer stretch than the right one. Therefore, we expected an 
increased risk of CVA, probably somewhat higher for RT on the left side. Overall, we 
found no increased risk of CVA. When analyzing by laterality, we observed an increased 
risk of TIA among women irradiated on the left supraclavicular region (HR 2.00; table 
5, see footnote), whereas no such risk increase was found for the right side (HR 0.84). 
No left-right difference was observed for stroke, however. Although there were some 
differences in fractionation schedules used in our study population, all schedules had 
a more or less equivalent biological effective dose. Consequently, we did not expect 
any differences in risk between these fractionation regimens. 
HT such as tamoxifen increases the risk of venous thromboembolism, and some recently 
published studies have investigated risk of stroke associated with tamoxifen.28-30 
Results from a meta-analysis by Bushnell and Goldstein8 showed an elevated risk of 
ischemic stroke (RR 1.82; 95% CI 1.41 - 2.36). However, the International Breast Cancer 
Intervention Study-I prevention study28 and the nested case-control study by Geiger et 
al.30 did not demonstrate a significantly increased risk of stroke with tamoxifen. In our 
study, we observed a nearly two-fold elevated risk of stroke in patients treated with HT. 
However, tamoxifen is often prescribed for metastasized BC. Therefore, the association 
with tamoxifen may be confounded by the presence of active disease, which in itself 
may predispose to thrombosis26 and thereby to ischemic stroke.31 The separate effects 
of active disease and HT could not be disentangled in earlier studies.28,30 Therefore, we 
assessed the influence of HT on the risk of stroke separately in patients without signs 
of relapse and again observed a (nonsignificantly) increased risk of stroke (HR 2.14).
Our recent study on cause-specific mortality in BC patients already showed a (non-
significant) 16% decrease in overall mortality from stroke.20 Importantly, this study 
showed no mortality increase from stroke during the first 10 years of follow-up, 
justifying our decision to focus on 10-year survivors of BC in the current study. There 
are several explanations for reduced risk of stroke in long-term BC survivors compared 
with the general population. First, the risk profile for BC (e.g., late menopause) may 
be protective against (cerebro-)vascular disease.32 In addition, women may opt for a 
healthier lifestyle (e.g., more exercise, healthier diet) after BC diagnosis, which would 
reduce their risk profile for stroke even more.33,34  Although we did not observe a more 
favorable risk profile in the study population compared with the general population, 
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our BC cohort may have been subject to more subtle changes in risk profile during 
follow-up (e.g., dietary changes, less smoking rather than cessation of smoking). 
Hypertension was even more frequently diagnosed in our BC population than in the 
general female population, probably as a result of surveillance bias. Paradoxically, this 
might explain the reduced risk of stroke. BC patients with known hypertension will 
receive treatment and thus reduce their risk of stroke, whereas a high proportion of the 
general population with hypertension may not be correctly diagnosed and thus will 
remain untreated. Finally, particularly in this cancer center-based study population, 
we may have studied BC patients with higher socioeconomic status, which has been 
reported to be associated with lower rates of vascular disease.35,36 
Strengths of our study include the availability of data on all primary and follow-up 
treatments, including radiation fields, and on cerebrovascular risk factors. Follow-up 
was near complete and very long, with over 30% of patients followed for more than 
20 years. 
A potential weakness of our study concerns underreporting of CVA diagnoses. However, 
a study on cardiovascular risk in the same study population37 rendered a significant 
1.3–fold increased risk of cardiovascular disease, which was comparable to results 
from other studies.2,5,38 In both studies on vascular events, we obtained information 
from GPs for the large majority of patients because a pilot study had shown that 20% 
of vascular events were not registered in oncologic records. Furthermore, since the 
GP was the source of information for both observed events and the reference rates 
used for comparison, any underreporting by GPs would not affect the validity of our 
results.
Although we had information on cardiac risk factors at baseline and also at follow-
up, it was not always available at the time we were most interested in (i.e. at 10 years 
after first treatment). We used hypertension, DM, and hypercholesterolemia as fixed 
covariates in the analysis with a positive score obtained at any point in time. Although 
this approach may have introduced some misclassification, this would be expected to 
bias our risk estimates to unity. As for smoking, this problem was largely avoided by 
using separate categories for smokers who continued smoking until end of follow-up 
and for ex-smokers (those who stopped at the time of BC diagnosis).
In conclusion, no association between stroke risk and irradiation to the supraclavicular 
nodes was found in our BC population. Although adjuvant HT1 clearly improves BC 
survival, physicians should be aware of the increased risk of stroke after HT in long-
term BC survivors.
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Abstract
Background
Information on clinically verified stroke and transient ischemic attack (TIA) following 
Hodgkin’s lymphoma is scarce. We quantified the long-term risk of cerebrovascular 
disease associated with the use of radiotherapy and chemotherapy in survivors of 
Hodgkin’s lymphoma, and explored potential pathogenic mechanisms.
Methods
We performed a retrospective cohort study among 2201 5-year survivors of Hodgkin’s 
lymphoma treated before age 51 between 1965 and 1995. We compared incidence rates 
of clinically verified stroke and TIA with the general population. We used multivariable 
Cox-regression techniques to study treatment-related and other risk factors.
Results
After a median follow-up of 17.5 years, 96 patients developed cerebrovascular disease 
(55 stroke, 31 TIA, 10 TIA and stroke; median age 52 years). Most ischemic events were 
of large-artery atherosclerotic (36%) or cardioembolic subtype (24%). The standardized 
incidence ratio for stroke was 2.2 (95% confidence interval (CI) 1.7-2.8); and 3.1 for TIA 
(95% CI 2.2-4.2). The risks remained elevated after prolonged follow-up. The cumulative 
incidence of ischemic stroke or TIA 30 years after Hodgkin’s lymphoma treatment was 
7% (95% CI 5-8%). Radiation to the neck and mediastinum was an independent risk 
factor for ischemic cerebrovascular disease (Hazard ratio 2.5; 95% CI 1.1-5.6). Treatment 
with chemotherapy was not associated with an increased risk. Hypertension, diabetes 
mellitus and hypercholesterolemia were associated with the occurrence of ischemic 
cerebrovascular disease, whereas smoking and overweight were not.
Conclusion
Patients treated for Hodgkin’s lymphoma experience a substantially increased risk of 
stroke and TIA, associated with radiation to the neck and mediastinum. Physicians 
should consider appropriate risk-reducing strategies.
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Introduction
The prognosis of patients diagnosed with Hodgkin’s lymphoma has significantly 
improved during the last decades; as a consequence many patients will become 
long-term survivors. During follow-up, therapy-related complications have become 
an important issue, especially in young adult survivors. The spectrum of late 
complications following curative therapy is diverse and includes impaired fertility, 
second malignancies and cardiovascular disease.1-6 Presently, only few studies 
considered stroke and transient ischemic attack (TIA) as the outcome of interest.7,8 In 
addition, none of these were able to compare the incidence of clinically verified stroke 
and TIA to the general population.
In Hodgkin’s lymphoma patients, both the carotid arteries and the heart are exposed 
to radiotherapy in case of mantle field irradiation. These patients could experience 
an increased risk of cerebrovascular disease by accelerated atherosclerosis resulting 
in carotid stenosis. Stroke and TIA risk may be further increased by cardioembolisms 
following radiation-induced cardiac disease. Those Hodgkin’s lymphoma patients 
who are treated with chemotherapy are at risk for chemotherapy-induced vascular 
toxicity, which may result in stroke. Especially acute occurring stroke, possibly due to a 
hypercoagulable state, is associated with antineoplastic agents such as L-asparaginase, 
5-fluorouracil, cisplatin, methotrexate and cyclophosphamide.9-11 These agents are not 
part of standard treatments for Hodgkin’s lymphoma, and the long term effects are not 
yet defined. Furthermore, anthracycline-induced heart failure12 or cardiomyopathy 
could result in an increased risk for stroke and TIA. 
In females, premature menopause induced by gonadotoxic chemotherapy5 may be 
a risk factor for late occurring cerebrovascular disease, as shorter lifespan of ovarian 
activity is associated with an increased risk for ischemic stroke.13
Until now, only few studies have reported on clinically verified stroke in long-term 
survivors of Hodgkin’s lymphoma.7,8 It has also not been analyzed which pathogenic 
mechanisms contribute to stroke incidence. We examined the incidence of both stroke 
and transient ischemic attack (TIA) in a large cohort of Hodgkin’s lymphoma survivors 
in the Netherlands. We restricted this study to patients who survived more than 5 years 
because the risk of vascular events associated with radiotherapy seems to emerge after 
5 years or more.7,14,15 The acute effects of the first-line treatment, e.g. acute occurring 
stroke, are beyond the scope of our study. 
Unique features of our study include the relatively young age of the cohort (< 51 
years at diagnosis), clinically verified strokes and TIAs, near complete follow-up, 
the assessment of cerebrovascular disease according to radiation fields and type of 
chemotherapy, and the availability of cerebrovascular risk factors. 
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Methods
Data collection procedures
We performed a cohort study among patients who were treated at 4 cancer centers/ 
University hospitals in The Netherlands (the Netherlands Cancer Institute-Antoni 
van Leeuwenhoek Hospital (NKI/AVL) in Amsterdam, Erasmus MC - Daniel den Hoed 
Cancer Center (EMC/DdHK) in Rotterdam, Leiden University Medical Center (LUMC) in 
Leiden, the Emma Children’s Hospital/Academic Medical Center (EKZ) in Amsterdam). 
Patients were younger than 51 years at treatment for Hodgkin’s lymphoma (1965-
1995) with either radiotherapy and/or chemotherapy. Patients were excluded if 
they had been treated with radiotherapy or chemotherapy before the diagnosis of 
Hodgkin’s lymphoma. Patient selection and methods of data collection in NKI/AVL 
and EMC/DdHK have been described in detail previously1,3,16,17; in the other centers 
methods were comparable. Data were collected directly from the medical records. In 
case the information could not be obtained from the medical record, questionnaires 
were sent to general practitioners and attending physicians. Collection of follow-up 
data for the current study took place between December 2004 and June 2008. Medical 
follow-up was complete for 94% of the cohort (51 patients had moved abroad, 78 were 
discharged from the primary hospital and attending physicians elsewhere could not 
be reached). We collected the following information: date of Hodgkin’s lymphoma 
diagnosis, treatment modalities of primary as well as salvage treatment for Hodgkin’s 
lymphoma, (i.e., radiation fields, cytostatic agents, and number of cycles), dates of stroke, 
TIA and other cardiovascular diseases, cerebrovascular risk factors, age at menopause, 
date of diagnosis and treatment of second malignancies, date of most recent medical 
information or date of death and primary cause of death. Smoking, weight, height 
and overweight were recorded both at the date of diagnosis of Hodgkin’s lymphoma 
and at the end of follow-up. Cerebrovascular risk factors were assessed according to 
clinical guidelines. Of the 2253 5-year survivors identified, 39 were excluded, because 
follow-up for cardiovascular diseases was less than 5 years following treatment for 
Hodgkin’s lymphoma, 6 were excluded because they developed a second malignancy 
that was treated with radiotherapy or chemotherapy within the first 5 years following 
treatment, and another 7 individuals were excluded because they developed a stroke 
or TIA before or within the first 5 years after treatment of Hodgkin’s lymphoma, leaving 
2201 patients eligible for analyses.
Outcome definition
Cases were defined as cohort members who developed a stroke or TIA 5 years or more 
after first treatment for Hodgkin’s lymphoma. Stroke or TIA diagnoses were verified by 
treating neurologists or general practitioners, who provided additional information 
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on type of stroke (ischemic/hemorrhagic), vascular territory (carotid or vertebrobasilar 
system), origin of stroke or TIA. Stroke etiology was further assigned using the TOAST 
criteria (large-artery atherosclerosis, cardioembolism, small-vessel occlusion, stroke of 
other determined etiology and stroke of undetermined etiology.18 We also collected 
data on treatment and clinical outcome (on average) 3 months after the event according 
to the Modified Rankin Score (see table 1 for detailed description).19 TIA was defined as 
any new neurological deficit (either ocular or cerebral) that resolved completely within 
24 hours. Stroke was defined as any new neurological deficit (either ocular or cerebral) 
that persisted > 24 hours or ended in death within 30 days.
Treatment
Dates of primary as well as first salvage treatment with radiotherapy and chemotherapy 
were recorded, as was detailed information on radiation fields, chemotherapeutic 
agents and number of cycles. Patients were usually treated in or according to EORTC 
(European Organization for Research and Treatment of Cancer) trials.20 The distribution 
of radiation fields is given in figure 1, based on individual treatment data, for primary 
as well as salvage treatment. Radiotherapy techniques changed over the years. In 
the 1960s, patients were treated with cobalt-60 or orthovoltage therapy; from the 
1970s onward, linear accelerators were used (usually 8 MV photons). Individual blocks 
were used to shield normal tissues as much as possible. Shielding of the distal part 
of the mediastinum was sometimes performed from the late 1980s onward in case 
there was no spread of disease below the aortic notch. The vast majority of cervically 
irradiated patients (82%) received a classical mantle field (at extended source skin 
distance involving the axillary, mediastinal and neck nodes), including the common 
carotid arteries, heart and thoracic aorta (figure 2). In addition, most patients were 
treated with 1 field per day only. The procedure of using 2 fields per day was gradually 
introduced in the late 1980s. Patients usually received 40 Gy (36-44 Gy) in fractions of 
2.0 Gy. Historically, patients were treated to doses of 40 Gy and in the era that effective 
chemotherapy was not available they were sometimes re-irradiated for recurrences. 
In addition, compensation for dose inhomogeneity was not routinely performed in 
the first decades of the studied period and hotspots in the neck and axilla could be 
as high as 20-30% above the prescribed doses.21 However, information on radiation 
techniques, radiation doses and fractionation schedules for individual patients was 
not collected. 
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Figure 1. Applied radiation-fields in study population (n=2201).
 
Mantle field alone 
(n=1139) 
Radiotherapy 
(n=2014) 
Infradiaphragmatic irradiation alone 
  
(n=116) 
Supradiaphragmatic 
irradiation (n=1857) 
(partially) unknown 
radiation fields (n=41) 
Mantle field 
(n=1415) 
Supraclavicular irradiation alone 
(n=52) 
Neck + mediastinal irradiation  
(no mantle field) (n=236) 
Neck irradiation,  
no mediastinal irradiation (n=84) 
Mediastinal irradiation,  
no neck irradiation (n=70) 
Mantle field + 
pelvic irradiation (n=276) 
From the 1960s to the 1980s chemotherapy consisted mainly of MOPP 
(mechlorethamine, vincristine, procarbazine, prednisone). In the 1980s, anthracycline-
containing regimens such as MOPP/ABV (mechlorethamine, vincristine, procarbazine, 
prednisone/doxorubicin, bleomycin, vinblastine) and ABVD (doxorubicin, bleomycin, 
vinblastine, and dacarbazine) were introduced as a part of the primary treatment.
Figure 2. Schematic representation of the radiotherapy of the mediastinum and neck including heart, aorta, 
carotid arteries (in red).
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Statistical analyses
We compared the incidence of stroke and TIA in the study population with the 
incidence in the Dutch population, taking into account the person-years of observation 
in the cohort (by age, calendar period, and follow-up interval).3 Incidence data of the 
Continuous Morbidity Registration-Nijmegen, derived from several general practices 
from representative regions in the Netherlands, were used as reference rates.22 This 
registry has collected data on the incidence of TIA and stroke for the period from 1972 
to 2000, allowing for multiple separate diagnoses per person but recording only the 
first of a specific diagnosis per person. There is no distinction between ischemic and 
hemorrhagic strokes in this registry. Follow-up started 5 years after the first treatment 
for Hodgkin’s lymphoma and ended at date of diagnosis of stroke or TIA, date of 
diagnosis of a second malignancy treated with radiotherapy or chemotherapy, date 
of most recent medical information, or date of death, whichever came first. Observed 
numbers were based on all first events of stroke and TIA occurring during time at risk. 
Strokes or TIAs that occurred after treatment of a second malignancy were therefore 
not included in the analysis.  Hodgkin lymphoma survivors may die (from other causes) 
before they can develop cerebrovascular disease, especially with prolonged follow-
up. Therefore, we calculated the cumulative incidences of stroke, TIA and ischemic 
stroke/TIA with adjustment for competing risks of death due to any cause using S-plus 
statistical software (Insightful, Seattle, WA), including user-written functions.23
The standardized incidence ratios (SIRs) of the observed and expected numbers of 
stroke and TIA in the study population were determined, and the confidence intervals 
(CIs) of the SIRs were calculated using exact Poisson probabilities of observed 
numbers.24 P- values for tests for trend were two-sided and were calculated using chi-
square test statistics. Absolute excess risk was calculated by subtracting the expected 
number of strokes or TIAs in our cohort from the number observed and dividing by 
person-years at risk (expressed per 10,000 person-years).
To study the effects of different treatments taking into account several covariates, we 
performed multivariate Cox-regression analyses. As the proposed mechanisms for 
treatment-induced stroke and TIA are thought to cause ischemic events, we excluded 
hemorrhagic strokes and strokes of unknown type in these analyses. In case of multiple 
events, time at risk ended at date of the first stroke or TIA. All treatment-related 
exposure variables were analyzed time-dependent. We calculated hazard ratios (HR) 
as a measure of relative risk and 95% CIs to describe the precision of our estimates. 
We evaluated the proportional hazards assumption by assessing log minus log curve 
{ln [-ln (S)]} and by fitting interaction terms between treatment categories as well 
as covariates and the logarithm of follow-up time. No violations of the proportional 
hazards assumption were observed. Models were fitted with the use of SPSS statistical 
software (SPSS Inc, Chicago, IL).
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Results
During follow-up (median 17.5 years) 96 patients developed a stroke or TIA (55 strokes, 
31 TIAs and 10 patients with both a TIA and a stroke). Of the 65 strokes, 57 were ischemic, 
7 were hemorrhagic (incl. 2 subarachnoid hemorrhages), and in 1 case the type could 
not be verified. Median time to first stroke or TIA was 17.4 years (range 5.1 to 37.6 
years). In total 88 individuals developed at least 1 ischemic stroke or TIA (47 ischemic 
strokes, 31 TIAs and 10 both ischemic stroke and TIA). Thirty-five of the ischemic strokes 
and TIAs occurred before age 51, and can be defined as ‘young strokes’. Most ischemic 
events were of large-artery atherosclerotic or cardioembolic subtype (table 1). Duplex 
ultrasonography revealed in 17% a significant (>50%) stenosis of the carotid artery. 
The majority of ischemic strokes and TIAs were pharmacologically treated. Twenty-two 
percent of the patients suffering from ischemic stroke had a poor clinical outcome 
(table 1).
The cumulative incidence of ischemic stroke or TIA accounting for death as a competing 
risk 30 years after first treatment was 7% (95% CI 5-8%), the separate cumulative 
incidences of stroke and TIA were 5% (95% CI 4-6%) and 3% (95% CI 2-4%) at that time, 
respectively (figure 3).
Figure 3. The cumulative incidence of ischemic stroke and TIA following Hodgkin’s lymphoma treatment.
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Table 1. Clinical characteristics of first ischemic strokes and TIAs. 
Ischemic stroke* TIA*
n=49 (%) n=39 (%)
Age at ischemic stroke/TIA
Median age (min-max) 51.4 (27.4-79.9) 54.4 (32.7-80.6)
< 50 years 22 (45%) 13 (33%)
≥ 50 years 27 (55%) 26 (67%)
Hemisphere
Right 19 (39%) 7 (18%)
Left 20 (41%) 20 (51%)
Both 6 (12%) 5 (13%)
Unknown 4 (8%) 7 (18%)
Vascular territory
Carotid 39 (76%) 30 (77%)
Vertebrobasilar 9 (18%) 4 (10%)
Both 2 (4%) 5 (13%)
Unknown 1 (2%) 0 -
Etiology ischemic event
Large-artery atherosclerosis 21 (43%) 11 (28%)
Cardioembolism 9 (18%) 12 (31%)
Small vessel occlusion 3 (6%) 0 -
Other determined etiology 1 (2%) 1 (3%)
Undetermined etiology 7 (14%) 5 (13%)
Unknown 8 (16%) 10 (26%)
Duplex ultrasonography
Carotid artery
- No stenosis 20 (41%) 16 (41%)
- 30-50% stenosis 2 (4%) 3 (8%)
- > 50% stenosis 10 (20%) 5 (13%)
Vertebrobasilar stenosis 2 (4%) 0 -
Not performed 13 (27%) 11 (28%)
Unknown 2 (4%) 4 (10%)
Treatment 
Antiplatelets/anticoagulants 40 (82%) 34 (87%)
Carotid endarterectomy 2 (4%) 2 (5%)
No treatment 7 (14%) 2 (5%)
Unknown 0 - 1 (3%)
Clinical outcome †
No symptoms (MRS 0) 9 (18%) 39 (100%)
Mild symptoms (MRS 1-3) 29 (59%) 0 -
Severe symptoms (MRS 4-5) 2 (4%) 0 -
Dead (MRS 6) 9 (18%) 0 -
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* Not including 8 ischemic strokes that occurred after a TIA, 7 hemorrhagic strokes, 1 stroke of unknown type, 
and 2 TIAs that occurred after an ischemic stroke. † Modified Rankin Score (MRS): 0: No symptoms at all; 1: 
No significant disability despite symptoms; able to carry out all usual duties and activities; 2: Slight disability; 
unable to carry out all previous activities, but able to look after own affairs without assistance; 3: Moderate 
disability; requiring some help, but able to walk without assistance; 4: Moderately severe disability; unable 
to walk without assistance and unable to attend to own bodily needs without assistance; 5: Severe disability; 
bedridden, incontinent and requiring constant nursing care and attention; 6: Dead
Compared to the general population, patients experienced an about 2-fold increased risk 
for stroke (SIR 2.2; 95% CI 1.7-2.8) and a 3-fold increased risk for TIA (SIR 3.1; 95% CI 2.2-4.2), 
resulting in 12 excess cases of stroke and 9 excess cases of TIA per 10,000 persons per 
year. There were significant trends of increasing SIRs with younger age at first treatment 
(p=0.004 for stroke and p=0.01 for TIA), but no increasing or decreasing trends with longer 
follow-up time or treatment period. There were no clear differences between men and 
women, and SIRs were only increased among those treated with radiotherapy alone, or 
combined modality treatment (table 2).
The multivariate Cox-regression analysis showed that patients treated with neck irradiation 
together with mediastinal irradiation experienced a significantly increased risk for ischemic 
stroke or TIA, compared to those treated with chemotherapy or infradiaphragmatic 
irradiation alone (HR 2.5; 95% CI 1.1-5.6) (table 3). Most of these patients (86%) received 
mantle field irradiation (figure 1). Neither anthracycline-containing chemotherapy, nor 
other chemotherapy was associated with an increased risk for ischemic cerebrovascular 
disease. Hypertension was an independent risk factor for ischemic stroke or TIA, 
hypercholesterolemia and diabetes mellitus were positively but non-significantly associated 
with ischemic cerebrovascular disease. Smoking and overweight were not associated with 
ischemic stroke or TIA (table 3). We did not find any evidence that premature menopause 
or gonadotoxic chemotherapy (related to cumulative procarbazine exposure)5 was 
associated with an increased risk for ischemic stroke and TIA among females (table 4).
Of the 1651 patients treated with mediastinal and neck irradiation, 21% (n=348) developed 
cardiac disease (heart failure, myocardial infarction, arrhythmias, or valvular disease) before 
the occurrence of ischemic stroke, TIA or end of follow-up. This proportion was substantially 
lower among those treated with other radiation fields or without radiotherapy (56/509 
= 11%). However, the risk to develop ischemic stroke or TIA in the period between first 
treatment for Hodgkin’s lymphoma and end of follow-up among patients treated with 
mediastinal and neck irradiation did not differ from the risk in the same period among 
those who did not develop cardiac disease before end of follow-up (adjusted HR 0.6; 95% CI 
0.4-1.1). On the other hand, when patient-time after the occurrence of cardiac disease was 
compared to patient-time before cardiac disease in a time-dependent analysis, we found 
that among patients treated with mediastinal and neck irradiation the risk for ischemic 
stroke or TIA was 2-fold increased after cardiac disease compared to before (adjusted HR 
2.1; 95% CI 1.2-3.7).
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Table 3. Cox regression analyses of potential risk factors for ischemic stroke or TIA following treatment for 
Hodgkin’s lymphoma.
Risk factor Patients Cases HR  (95%  CI) HR  (95%  CI)
n=2201 n=88 Univariate Multivariate*
Female sex (vs male) 968 40 1.0 (0.6 - 1.5) 0.8 (0.5 - 1.3)
Radiotherapy
No supradiaphragmatic irradiation 303 7 1 (Ref ) 1 (Ref )
Supraclavicular/neck irradiation 136 5 2.2 (0.7 - 7.0) 2.3 (0.7 - 7.6)
Mediastinal irradiation 70 1 1.0 (0.1 - 8.5) 1.2 (0.1 - 9.8)
Mediastinal + neck irradiation 1651 75 2.2 (1.0 - 4.7) 2.5 (1.1 - 5.6)
Partially unknown radiation fields 41 0 - -
Chemotherapy
No chemotherapy 609 32 1 (Ref ) 1 (Ref )
Anthracyclines 690 17 1.1 (0.6 - 2.1) 1.3 (0.7 - 2.5)
Other chemotherapy 902 39 0.8 (0.5 - 1.2) 1.0 (0.6 - 1.7)
Cerebrovascular risk factors
High cholesterol (vs no/unknown) 203 25 2.6 (1.6 - 4.2) 1.6 (1.0 - 2.6)
Hypertension (vs no/unknown) 282 36 3.3 (2.1 - 5.0) 2.1 (1.3 - 3.3)
Diabetes mellitus (vs no/unknown) 120 13 2.7 (1.5 - 4.9) 1.5 (0.8 - 2.7)
Smoking (vs never/unknown)
- Past 634 23 0.9 (0.5 - 1.4) 0.9 (0.5 - 1.4)
- Current 373 14 1.0 (0.6 - 1.8) 1.2 (0.7 - 2.3)
BMI >30 kg/m2 (vs ≤30 kg/m2) 199 12 1.6 (0.8 - 2.9) 1.2 (0.6 - 2.2)
HR: Hazard ratio, CI: confidence interval, BMI: body mass index.
* Adjusted for age at first treatment for Hodgkin’s lymphoma, pelvic irradiation, and each other
Increased risk of stroke and TIA in survivors of Hodgkin’s lymphoma
67
Table 4. The influence of premature menopause and gonadotoxic chemotherapy on risk of ischemic stroke 
or TIA following treatment for Hodgkin’s lymphoma.
Patients Cases HR  (95%  CI)
n=2201 n=88 Multivariate
Premature menopause (model 1*)
  Male 1233 48 1.3 (0.7 - 2.2)
  Female
Menopause at age 41 or later 298 18 1 (Ref )
Menopause before age 41 213 8 1.0 (0.4 - 2.4)
Age ≤ 41 and premenopausal at end of study 191 2 1.7 (0.4 - 8.1)
Age at menopause unknown 266 12 1.0 (0.5 - 2.1)
Gonadotoxic therapy
Overall (model 2†)
No CT/ CT without procarbazine ‡ 883 47 1 (Ref )
Alkylating CT, ≤8.4g/m2 procarbazine 733 28 1.3 (0.6 - 2.8)
Alkylating CT, >8.4g/m2 procarbazine 308 9 1.8 (0.7 - 4.6)
No pelvic irradiation 1742 67 1 (Ref )
Pelvic irradiation 459 21 1.3 (0.7 - 2.2)
  Males (model 3†)
No CT/ CT without procarbazine ‡ 467 26 1 (Ref )
Alkylating CT, ≤8.4g/m2 procarbazine 427 15 1.2 (0.4 - 3.9)
Alkylating CT, >8.4g/m2 procarbazine 187 6 1.7 (0.4 - 6.5)
No pelvic irradiation 928 35 1 (Ref )
Pelvic irradiation 305 13 1.3 (0.7 - 2.6)
  Females (model 4†)
No CT/ CT without procarbazine ‡ 416 21 1 (Ref )
Alkylating CT, ≤8.4g/m2 procarbazine 346 13 1.2 (0.4 - 3.7)
Alkylating CT, >8.4g/m2 procarbazine 121 3 2.1 (0.5 - 9.2)
No pelvic irradiation 814 32 1 (Ref )
Pelvic irradiation 154 8 1.4 (0.6 - 3.2)
HR: Hazard ratio, CI: confidence interval, CT: chemotherapy.
* Adjusted for age at first treatment for Hodgkin’s lymphoma, supradiaphragmatic radiation field, 
chemotherapy, cerebrovascular risk factors (smoking, BMI>30 kg/m2, diabetes mellitus, hypertension, 
hypercholesterolemia) and each other.
† Adjusted for sex, age at first treatment for Hodgkin’s lymphoma, supradiaphragmatic radiation field, other 
chemotherapy, cerebrovascular risk factors (smoking, BMI>30 kg/m2, diabetes mellitus, hypertension, 
hypercholesterolemia) and each other.
‡ Unknown CT/ unknown procarbazine dose was modeled as a separate category.
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Discussion
To the best of our knowledge, this is the first long-term cohort study assessing the 
incidence of clinically verified stroke and TIA in survivors of Hodgkin’s lymphoma, taking 
into account cerebrovascular risk factors as well as radiation fields, that compared 
the incidence to the general population. Overall, stroke and TIA risks are increased 
compared to the age- and sex-matched control population. Risks were especially 
elevated among patients treated at a young age (< 21 years), and remained increased 
for at least 25 years. The excess burden of stroke and TIA are 10 and 9 cases per 10,000 
patients per year, respectively, implying 1 excess case of stroke and TIA each among 
100 5-year survivors followed for 10 years.  Radiation on the neck and mediastinum 
proved a significant risk factor for the occurrence of ischemic stroke and TIA. Other 
significant risk factors were age at treatment and hypertension.  
Recently, the Childhood Cancer Survivor Study (CCSS) reported on self-reported 
incidence and risk factors for stroke in childhood Hodgkin’s survivors.7 Twenty-four late 
occurring strokes were observed in a cohort of 1926 survivors of childhood Hodgkin’s 
lymphoma (relative risk (RR) 4.32; 95% CI 2.01-9.29). Patients irradiated with mantle 
fields even experienced a higher RR for stroke (5.62; 95% CI 2.59-12.25). Our results 
are in line with the CCSS, although the RRs we found are lower than those calculated 
by the CCSS. A probable explanation is that the CCSS population is younger, and in 
our data younger age at first treatment was associated with a greater risk increase 
of stroke. However, in the youngest group of our cohort, the risk is still lower than 
reported by CCSS. It is possible that self-report of stroke can lead to overestimation of 
the true incidence of the disease. For patients it is difficult to distinguish a stroke from 
other focal neurological disorders like epileptic seizures and e.g. collapses. 
The most important risk factor for ischemic stroke and TIA in our study was irradiation 
to the neck and mediastinum. Studies in survivors of head and neck cancer showed 
that high-dose radiotherapy (60-66 Gy) to the neck is associated with a significantly 
increased risk of stroke.14,15,25 The time interval from radiotherapy until stroke diagnosis 
was shorter in head and neck cancer patients (median time interval 10.9 years, 
range 1.3 to 21.0) than in the Hodgkin’s lymphoma-survivors (median time interval 
17.4 years, range 5.1 to 37.6). We hypothesize that in relatively young Hodgkin’s 
lymphoma-survivors (median age at first treatment 27.1, range 3.1 to 50.9) with naïve 
atherosclerotic arteries, radiotherapy induces atherosclerosis. In contrast, in the older 
head and neck patients radiotherapy accelerates the already existing atherosclerotic 
lesions. Because radiation effects are presumed to be dose-related, mantle field 
irradiation (with a tumor dose of 30-40 Gy) may contribute to a longer time interval 
than the higher dose radiotherapy-schedules in head and neck patients. 
In concordance with Hull et al.,8 who studied risk factors for carotid and subclavian 
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disease among Hodgkin’s lymphoma patients, we found that hypertension was an 
independent risk factor for ischemic stroke and TIA. In contrast, we were not able to 
confirm the high risk associated with diabetes mellitus. This could be due to coincidence 
or to the fact that Hull et al. studied a slightly different end-point, including not only 
stroke and TIA, but also subclinical carotid and subclavian stenosis.
Besides large-artery arthrosclerosis, another mechanism for ischemic stroke and TIA 
in these patients includes cardioembolisms. Hodgkin’s lymphoma survivors have an 
increased risk of radiotherapy-related cardiovascular disease like myocardial infarction 
and valvular dysfunction.3,8 We found that 24% of the ischemic strokes and TIAs had 
a cardioembolic etiology (table 1). We also found that after a patient had developed 
cardiac disease; the risk of subsequent ischemic stroke or TIA was 2-fold increased. 
Epidemiologic study of intermediate factors in the etiologic pathway of exposure 
and disease requires advanced statistical techniques.26 Unfortunately, in our study 
population numbers were too small to successfully apply these techniques.
Overall, stroke and TIA were diagnosed at a relatively young age (median 52 years, range 
24 to 80 years). The impact of stroke and TIA on quality of life of Hodgkin’s lymphoma-
survivors is high. In general, stroke is judged the sixth most common cause of reduced 
disability-adjusted life-years (DALY= sum of life years lost as a result of premature death 
and years live with disability adjusted for severity).27 In our cohort 13% of the patients 
with ischemic stroke had a poor clinical outcome (Modified Rankin Score ≥4). Among 
young strokes (age <51 at diagnosis) the proportion of patients with a poor clinical 
outcome was much lower than among patients who suffered from ischemic stroke 
at older ages (14% vs. 29%). Long-term prognosis of ischemic stroke in young adults 
(range 15 to 45 years) is generally limited, especially in terms of work activity: only 53% 
of young ischemic stroke patients return to work again.28 Functional independence is 
more favorable and is seen in 90%, which is comparable with our cohort (functional 
independence (Modified Rankin Score ≤3) in 86% (age <51)). 
Primary prevention for cardio- and cerebrovascular disease after radiotherapy has not 
yet been established. As cardiovascular risk factors, like hypertension, contribute to the 
elevated risk of ischemic stroke and TIA after radiotherapy,8,14 intervention in these risk 
factors after radiotherapy is important. Secondary preventive strategies after ischemic 
stroke and TIA in Hodgkin’s lymphoma-survivors are not different than in classic 
atherosclerosis and consist of antiplatelet and anticoagulant treatment according to 
the origin of stroke (non-cardiogenic versus cardiogenic). Special attention is needed 
for screening of the carotid arteries and for cardioembolisms in case of symptomatic 
long-term survivors of Hodgkin’s lymphoma. We do not advocate screening for carotid 
stenosis in asymptomatic patients because of the relatively low excess cases of stroke 
and TIA: about one excess case of stroke and TIA among 100 5-year survivors followed 
for 10 years.The best treatment for both asymptomatic and symptomatic carotid 
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artery stenosis is a matter of debate and should be patient-tailored. Both carotid 
endarterectomy and carotid artery stenting could be considered.29
Strong features of our study are near complete follow-up and the validation and 
outcome of stroke and TIA by information from the neurologist. We found that the 
proportion of strokes of the ischemic subtype (87%) was slightly higher compared to 
other population based series of strokes (54-88%).30-33 Another interesting finding was 
the distribution of large-vessel atherosclerosis versus cardioembolic etiology between 
ischemic strokes (43% vs. 18%) and TIAs (28% vs. 31%). In addition, significant carotid 
stenosis was, at least, present in 20% of the patients who suffered from ischemic stroke, 
and 13% of the patients who experienced a TIA (table 1). These proportions might be 
underestimated because ultrasonoghraphy was performed in only 73% of all stroke 
patients and in 72% of all TIA patients.
Unfortunately, precise information on administered radiation dose was lacking in our 
study. In the study by Hull et al.,34 the median low cervical radiation doses for patients 
who did and did not develop subclavian stenosis were 44Gy and 36Gy, respectively 
(p=0.002). However, the RRs of stroke were significantly elevated in patients treated 
between 1965-1985, while the RR was not significantly increased in patients treated 
between 1986-1995. This is suggestive of a dose effect, although it may also be due 
to fewer person-years with long-term follow-up, and associated lower power, among 
patients from the more recent era. The RRs of TIA, however, were similarly elevated 
throughout the calendar period of 1965-1995. Since then there have been substantial 
changes in radiation treatment for Hodgkin’s lymphoma with the use of lower doses, 
smaller treatment fields and more conformal techniques to limit dose inhomogeneity. 
It would be interesting to further examine radiation dose-response relationships in 
future studies covering patients treated after 1995, when both applied radiation doses 
and volume were reduced. 
Another limitation of our study is the proportion of missing data regarding the etiology 
of the ischemic strokes and TIAs (20% unknown). In some very disabled patients 
(Modified Rankin Score ≥4, 13%) no further research was performed by the treating 
neurologists for identification of the underlying cause. In the remaining patients we 
could not retrieve these data.
In summary, patients with Hodgkin’s lymphoma experience a 2- to 3-fold increased 
risk of stroke and TIA for a prolonged period after treatment. Radiation to the neck 
and mediastinum importantly contribute to cerebrovascular late effects. Especially 
young survivors of Hodgkin’s lymphoma are at increased risk of stroke and TIA, 
physicians should consider appropriate risk-reducing strategies such as treatment of 
hypertension, and lifestyle advice such as refraining from smoking.
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Abstract
Patients treated for head and neck tumors with local radiotherapy (RT) on the neck 
harbor an increased risk of stroke. This may be due to accelerated atherosclerotic 
changes within the RT-field; however, the real impact of local RT on the carotid artery 
remains debatable. 
The aim of the present study was to assess the difference in carotid wall thickness 
(intima-media thickness) in 42 unilaterally irradiated parotid tumor patients by 
performing B-mode ultrasonography.
A mean difference in intima-media thickness (IMT) of the irradiated compared with the 
non-irradiated carotid artery of 0.30 mm (p= 0.031) was found. A significant correlation 
was established with a longer post-RT interval (p= 0.008). 
RT on the neck is associated with increased  thickening of carotid IMT. Screening and 
treatment of additional cerebrovascular risk factors which contribute to further IMT 
thickening and stroke development is recommended, especially in RT patients with a 
favorable prognosis.
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Introduction
Patients treated for head and neck tumors with local radiotherapy (RT) harbor an 
increased risk of stroke.1,2 The underlying mechanism has not been completely 
identified, but accelerated atherosclerosis of the vessels in the RT-field is thought 
to play an important role.3 This mechanism is corroborated by others4,5 who show 
a significant higher risk of carotid artery stenosis in patients irradiated on the neck 
compared with age- and sex-matched controls. In these studies, however, the effect of 
RT on the degree of carotid artery stenosis was compared with a healthy control group 
and could therefore give an overestimation of the effect of RT on vascular changes. 
This is caused by the fact that patients with head and neck tumors generally have 
more risk factors for atherosclerosis, especially nicotine abuse. 
B-mode ultrasonography is a reliable and non-invasive technique for assessing the 
inner wall thickness of the carotid artery. The inner wall is usually expressed as the 
intima-media thickness (IMT).6 Carotid plaques and increase of carotid IMT are shown 
to be independent predictors of cerebrovascular disease.7-9 We therefore studied the 
effect of RT on the carotid artery IMT in unilaterally irradiated patients, allowing the 
patient’s contra-lateral carotid artery to serve as an internal control. 
Patients and methods
Patients 
We studied forty-two consecutive patients from whom follow-up could be obtained. 
All patients had received postoperative unilateral RT on the neck. Two types of patients 
were studied: (1) patients with parotid carcinoma and (2) patients with pleomorphic 
adenoma in whom massive uncontrolled tumor spill or incomplete resection 
necessitated RT. All patients gave written consent to participate in the study. Patients 
who had also been treated with chemotherapy were excluded. 
Intima-media thickness
Two-dimensional carotid imaging studies were performed with a 7.5-MHz linear 
array transducer.10 The IMT was defined as the distance between the echogenic 
line representing the blood-intima interface and the echogenic line representing 
the media-adventitia interface. The IMT was measured on the posterior wall in the 
longitudinal plane in an anterolateral approach with the transducer head perpendicular 
to the vessel. IMT was measured either at the internal carotid artery (ICA) or at the 
bifurcation, or both, depending on the anatomical borders of the RT-field (figure 1). 
The difference in IMT was calculated as the IMT at the irradiated side minus the IMT at 
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the non-irradiated side. If the bifurcation was also located in the RT-field, the difference 
in IMT was calculated at this level as well. The mean difference in IMT at both locations 
was used for this group of patients.
Figure 1. Lateral view of the neck and face of a patient irradiated for a parotid carcinoma on the right side, 
illustrating the skin changes in the former RT-field. Note the demarcation of the RT-field and the association 
with the carotid artery.
Radiation therapy
The radiation technique was two lateral oblique-wedged fields that encompass the 
parotid gland and upper neck nodal regions with 4 or 8-MV photons. These fields 
included the unilateral carotid artery. The estimated dose of RT was 90%-100% of 
the total administered dose (figure 2). RT-variables including time of RT, dose, and 
fractionation schedule were assessed. Post-RT-interval was determined as the time 
span between RT and IMT measurement (years).
Measurements of other covariates
All patients completed a standardized questionnaire to assess patients’ and family 
history of cerebrovascular disease. Blood pressure was measured twice on the right arm 
in sitting position using a mercury sphygmomanometer. Hypertension was defined 
when systolic blood pressure ≥ 160 mm Hg and/or a diastolic blood pressure ≥ 95 
mm Hg in both measurements; and/or the use of blood pressure-lowering medication. 
Diabetes mellitus was considered present if the patient was taking oral anti-diabetics 
or insulin. Hypercholesterolemia was present if the patient was taking cholesterol-
lowering drugs. Smoking was considered present if the patient was a current smoker 
or had quit smoking less than 3 years ago. 
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Figure 2. Contrast-enhanced CT-scan at the level of the upper neck of a patient with a right-sided parotid 
carcinoma, illustrating the position of the carotid artery (white arrow) next to the jugular vein within the 
radiation fields (red lines represent 90% dose).
Statistical analysis
A paired t-test was conducted for comparison of the IMT at the irradiated versus the 
non-irradiated side. Stepwise linear regression analysis was used to examine the 
association between age at RT, sex, the post-RT-interval, other covariates, and the 
difference in IMT. We performed post-RT interval stratified analysis to investigate the 
effect of the post-RT interval on the IMT. 
Results 
Patients
Forty-two patients (20 males, 22 females) were included in the study, consisting of 43% 
patients with a parotid carcinoma and 57% patients with pleomorphic adenoma. The 
median age at RT was 47.4 years (range 23 to 77 years). The median post-RT interval 
was 9.8 years (range 3.4 to 27.2 years). 
The total therapeutic radiation dose ranged from 40 to 66 Gy and was delivered in 
fractions of 2.0 Gy. Patient characteristics and an outline of other covariates are 
summarized in table 1.
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Table 1. Characteristics of study population
 n %
Median age (yrs, range) 47 (23-77)
Gender
Male
Female
20
22
48
52
Tumor type 
Parotid carcinoma
Pleomorphic adenoma
18
24
43
57
Radiotherapy 
 40-50 Gy
 50-60 Gy
 > 60 Gy
2
31
9
5
74
21
Smoking
Current smoker
Smoking past
Non-smoker
12
12
18
29
29
43
Hypertension 7 17
Diabetes mellitus 0 0
Hypercholesterolemia 6 14
Atrial fibrillation 4 10
Family history cardiovascular disease 11 26
History cardiovascular disease 4 10
Intima-media thickness
Overall, the mean IMT on the irradiated side was 1.13 mm (standard deviation (SD) 0.85 
mm) and 0.83 mm (SD 0.51 mm) on the non-irradiated side. The mean difference in IMT 
was 0.30 mm (95% CI 0.03-0.57, paired t-test, p= 0.031, table 2). 
There was a linear relation between the IMT difference and the duration of the post-
RT interval (unstandardized ß (SE) =0.062 IMT-increase/year post-RT (0.020), p=0.008). 
Adjustment for other covariates did not alter the magnitude of the association. 
Stratification for post-RT-interval showed a mean difference in IMT of 0.67 mm during 
a post-RT interval of more than 10 years (p=0.007), whereas there was no difference in 
IMT during the first 10 years (table 2). 
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Table 2. Intima-media thickness (IMT) (mm) of the irradiated carotid artery and the non-irradiated carotid 
artery, overall and divided in 10-year post-RT-intervals. 
Post-RT interval
Mean IMT (mm) carotid artery
RT-side                     non-RT side
∆ IMT (mm) p-value
Overall 1.13                            0.83 + 0.30 0.031
< 10 years 0.91                            0.96 - 0.05 > 0.05
≥ 10 years 1.35                            0.68 + 0.67 0.007
RT:radiotherapy
Occurrence of cerebrovascular accidents
Five patients had sustained a vascular ischemic event (3 TIA, 2 cerebral infarction) at 
a median of 11 years (range 5.9 to 13.1 years) following RT. In 4 of these 5 patients it 
occurred in the area of the irradiated carotid artery. The mean difference in IMT in these 
patients was 1.1 mm. One patient developed an infarction in the hemisphere contra-
lateral to the side of irradiation. This patient showed no difference in IMT (0 mm).
Discussion
Our study demonstrates that RT causes a significant increase in IMT on the irradiated 
carotid artery compared with the non-irradiated side. The difference in IMT is 
especially pronounced after a longer post-RT interval. The strength of our study was 
the comparison of the irradiated carotid artery to the patient’s contra- lateral non-
irradiated carotid artery. In this way we could eliminate all other risk factors and the 
difference can be ascribed to the effect of RT on the vascular tissue. However, it is 
necessary to mention that the presence of other vascular risk factors can aggravate 
the changes. 
A limitation of the study was the cross-sectional design. Selection of patients with 
favorable oncology and a good vascular prognosis could have led to selective survival. 
This possible selection bias could be responsible for a smaller IMT on the non-RT side in 
patients studied more than 10 years post-RT (0.68 mm) in comparison to those studied 
within 10 years (0.96 mm). Those with a large IMT (higher degree of atherosclerosis) 
have presumably already died.  Another restriction related to the cross-sectional 
design is the lack of follow-up within one patient. A longitudinal prospective study is 
needed to determine the development of radiation related vascular changes in time 
within individual patients. 
It has been postulated that RT induces acute endothelial damage, which in turn causes 
endothelial proliferation11 as well as chronic fibrosis of the media and occlusive changes 
of the vasa vasorum of the adventitia. These changes will produce atherosclerotic-
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like plaques resulting in vascular stenosis and thrombo-embolic processes.3 A large 
longitudinal study of 4466 (non-irradiated) subjects without a history of cardiovascular 
disease showed that an increment of 0.55 mm in wall thickness was associated with 
an approximate 40 percent increased risk of stroke.9 The increase in IMT in irradiated 
patients can be one of the causal factors leading to stroke. Moreover, the high incidence 
of vascular events that occurred in the territory of the irradiated carotid artery in our 
cohort favors this hypothesis.
Our study group consisted of relatively young patients (median age of 47 years at the 
time of RT) with a favorable prognosis. The vascular changes become increasingly 
prominent during the time span after RT. In general, these patients develop 
cerebrovascular ischemic complications at an earlier age than indicated by the 
incidence rates of cerebrovacular disease in non-irradiated patients.1,12 Both carotid 
endarterectomy13,14 and carotid stenting15 comprise options for intervention therapy 
in case of symptomatic carotid stenosis, although long-time follow-up results have not 
been reported. 
Next to the factor time, radiation dose contributes to the development of vascular 
changes after RT. Others showed that a minimum dose of 25-40 Gy is correlated with 
induction of these changes,16 but at doses of more than 40 Gy Chung and colleagues 
could not detect a dose dependent relationship when they compared high dose RT 
(≥ 65 Gy) with lower dose RT (< 60 Gy) and the severity of the post RT carotid changes 
on MRI angiography.17 In our cohort of 42 patients the RT doses varied from 40 to 66 
Gy; 74 % of patients had received a dose between 50 and 60 Gy. We were not able to 
detect a dose-response relationship. 
Our data support the hypothesis that RT is an independent risk factor for vascular 
disease, particularly after a post-RT-interval greater than 10 years. This finding has 
important implications for the pre-treatment screening and post-treatment follow-up 
of irradiated patients. Attention must be paid to identify and modify other risk factors, 
which further increase the risk of stroke in these irradiated patients.1 Longitudinal 
prospective studies are needed to analyze the IMT-changes over a longer time period 
and, to investigate whether treatment with thrombo-modulating agents, like statins 
or ACE-inhibitors, can prevent or diminish these changes following RT.
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Abstract 
Purpose
Patients who have been irradiated at the neck have an increased risk of symptomatic 
stenosis of the carotid artery during follow-up. Carotid Angioplasty and Stenting 
(CAS) can be a preferable alternative treatment to carotid endarterectomy which is 
associated with increased operative risk in these patients. 
Patients and methods
We performed a prospective cohort study of 24 previously irradiated patients who 
underwent CAS for symptomatic carotid stenosis. We assessed periprocedural and 
non-procedural events composed of TIA, non-disabling stroke, disabling stoke and 
death. Patency rates were evaluated on duplex ultrasound scans. Restenosis was 
defined as a stenosis of > 50% at the stent location.
Results
Periprocedural TIA-rate was 8% and periprocedural stroke (non-disabling) occurred in 
4% of patients. After a mean follow-up of 3.3 years (range 0.3 to 11.0 years) only one 
ipsilateral incident event (TIA) had occurred (4%). In 12% of patients a contralateral 
incident event was present: one TIA (4%) and 2 strokes (12%, 2 disabling strokes). 
Restenosis was apparent in 17%, 33% and 42% at respectively 3, 12 and 24 months, 
although none of the patients with restenosed vessels became symptomatic. The 
length of the irradiation to CAS interval proved the only significant risk factor for 
restenosis. 
Conclusion
The results of CAS for radiation induced carotid stenosis are favorable in terms of 
recurrence of cerebrovascular events at the CAS-side. 
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Introduction 
External neck irradiation is a risk factor for transient ischemic attack (TIA) and stroke, 
probably mediated by the development of carotid artery stenosis.1-4 The occurrence 
of clinical symptoms may be long (range 1 to > 20 years) after radiotherapy (RT).5 
With the therapeutic advancement of primary head and neck malignancies and the 
attendant increased long-term survival after RT, these patients are at high risk for the 
development of RT induced carotid artery stenosis; hence the need for evaluating its 
treatment.
Although RT-induced carotid stenosis can surgically be treated by carotid 
endarterectomy (CEA)6, this technique is challenging due to diminished healing 
capacities, scar tissue due to former radical neck dissection and /or the irradiation 
itself, compared with stenosis based on atherosclerosis. In addition,  the surgical access 
is considered more difficult because of a often, more proximally located stenosis in 
the common carotid artery.7 Therefore, the American Stroke Association guidelines 
state that Carotid Angioplasty and Stenting (CAS) can be considered for patients 
under specific conditions such as radiation induced stenosis.8 Although theoretically 
CAS could possibly overcome some of these limitations that exist for CEA, reliable 
empirical data on incident stroke and patency rates of CAS after RT induced carotid 
artery stenosis are sparse.9,10 
We therefore performed a prospective study to investigate incident cerebrovascular 
events and the occurrence of restenosis among 24 patients who were treated with 
CAS after RT. 
Subjects and Methods
Subjects and possible risk factors
We assembled a cohort of patients who underwent CAS for symptomatic RT induced 
carotid stenosis between the years 1998 and 2006 at the Neurointerventional 
Radiology department of two institutes (St Antonius Hospital, Nieuwegein and the 
University Medical Center Utrecht). Inclusion criteria were prior RT of the neck before 
CAS, complete periprocedural data of CAS and complete clinical follow-up. 
By medical record review, we collected baseline data including age, sex, neurological 
symptoms prior to stenting, vascular risk factors according to clinical guidelines 
hypertension (defined as either treatment for high blood pressure or a blood pressure 
that exceeded twice the limit of 95 mm Hg), diabetes mellitus, dyslipidemia/statin 
treatment, smoking (current, former and never), cardiovascular morbidity and previous 
CEA. We also took tumor type and oncological treatment regimen into account 
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including: RT-dose, RT–CAS interval and previous neck surgery (radical neck dissection 
and/or laryngectomy). Symptomatic carotid disease prior to stenting was diagnosed if 
the patient had experienced a TIA or stroke referable to the carotid lesion. 
Procedure
Diagnosis of carotid stenosis was made by duplex ultrasound (DUS), in combination 
with either computed tomographic (CT) angiography or magnetic resonance (MR) 
angiography. Pre-stent stenosis of the carotid artery was further graded on digital 
subtraction angiography according to the NASCET criteria.11 All patients were treated 
with CAS for symptomatic stenosis of their carotid artery, at either the common carotid 
artery (CCA), the internal carotid artery (ICA) or both, depending on the location of 
the stenosis. In all patients, CAS was performed in accordance with our previously 
described protocol.12,13 All procedures were performed under local anesthesia, from 
a groin approach. Procedures were performed by an experienced interventionalist. 
Technical failure was defined as residual stenosis of 30% graded on the digital 
subtraction angiography after the procedure. 
Follow-up
The whole cohort was followed for the occurrence of the following primary end points; 
TIA and (non) disabling stroke (either ipsilateral or contralateral of the CAS procedure) 
and death. TIA was classified as any neurological deficit (either ocular or cerebral) that 
resolved completely within 24 hours, non-disabling stroke if the modified Rankin score 
was ≤ 2 (on a scale of 0-5, with higher score indicating more disability), a disabling 
stroke if the modified Rankin score was 3 points of more.14 Death was categorized as 
death from stroke, death from vascular cause or death from other cause. 
Follow-up evaluations were performed by an independent stroke neurologist. 
In addition DUS were performed at 48 hr, 30 days, 3 and 12 months post-CAS and 
thereafter annually. If patients were not followed anymore in our tertiary centers, 
information on outcome events was collected by the general practitioner. Peri-
procedural complications were classified as events that occurred within 30 days 
after CAS. Non-procedural events were collected from 30 days after the procedure 
until the end of follow-up, i.e. the last surveillance by the neurologist or the general 
practitioner.
DUS was performed by an independent rater and consisted of the ipsi-and contralateral 
CCA (proximal and distal), ICA (proximal, middle and distal) and external carotid artery 
(ECA). The DUS criteria used in our vascular laboratory are based on the Strandness 
criteria.15 In terms of classification of the degree of ICA or CCA stenosis, we used the 
same velocity criteria in the post-stenting as for the pre-stenting situation. We measured 
the highest peak systolic (PSV) and enddiastolic velocities (EDV) in the stented artery 
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for grading the restenosis. Restenosis was defined as a stenosis of > 50%. Contralateral 
stenosis was graded as 50% or more. 
Endpoints
The primary endpoint was the occurrence of non-procedural incident cerebrovascular 
events (TIA, non-disabling, disabling stroke) and death during follow-up. 
The secondary endpoint was the occurrence of restenosis of the stented carotid artery 
during follow-up. Restenosis was defined as a stenosis of > 50% at the CCA or ICA at 
the treated side. 
Statistics
Statistical analyses were performed using the statistical software package SPSS 14.0 
(SPSS, Inc., Chicago, Il). Actuarial survival analysis was performed by Kaplan Meier life 
tables in order to analyze the occurrence of incident cerebrovascular events. 
Multivariate Cox proportional hazard models were used to assess the risk of the 
primary end points, adjusted for possible confounding factors including hypertension, 
diabetes mellitus, smoking, oncologic treatment (time interval between RT-CAS) and 
procedure related factors (previous neck operation, contralateral carotid disease). 
The relationship between restenosis at specific time points and potential risk factors 
(hypertension, diabetes mellitus, smoking, contralateral stenosis, previous neck 
operation and time-interval between RT and CAS) was assessed by means of sex and 
age adjusted logistic regression analysis. 
Results
Patient characteristics
We identified 24 patients who underwent CAS for symptomatic radiation induced 
carotid stenosis. The demographic characteristics, tumor en RT-status are presented 
in table 1. The mean time elapsed between RT and CAS was 13.1 years (SD 8.1). The 
contralateral carotid artery was occluded in 6 patients (25%), while 8 patients (33%) 
had a contralateral ACI stenosis of > 50%. In 12 patients (50%) a stenosis of more than 
50% was observed at the ipsilateral external carotid artery (ECA). 
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Table 1. Demographics of 24 patients undergoing CAS for radiation induced carotid stenosis.
Characteristics n= 24 (%)
Age  (years) (mean, SD) 68 (8.1)
Male 18 (75)
Tumor type
Larynxcarcinoma
Oropharynxcarcinoma
Lymphoma
Other
11 (46)
6  (25)
2  (8)
5 (21)
Radiotherapy
< 40 Gy
40-60 Gy
> 60 Gy
2 (8)
5 (21)
17 (71)
Time elapsed between RT-CAS (years, SD) 13.1 (8.1)
Previous operation
Lymph node dissection or laryngectomy
Carotid endarterectomy (ipsilateral)
13 (54)
2 (8)
Concomitant vascular risk factors
Hypertension
Smoking (current)
Diabetes mellitus
Hypercholesterolemia/ Statin treatment
Cardiovascular disease
13 (54)
5 (21)
3 (13)
11 (46)
5 (21)
Qualifying symptoms
TIA
Ischemic Stroke
14 (59)
10 (42)
Preprocedural stenosis
 50-69%
 70-89%
 90-99%
1 (4)
8 (33)
15 (63)
Lesion location of stenosis
Common carotid artery
Internal carotid artery
Both internal and common carotid artery
4 (17)
18 (75)
2 (8)
Contralateral carotid patency
Stenosis (50-99%)
Occlusion
8 (33)
6 (25)
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Outcomes
Technical and perprocedural angiographical success (i.e. a residual stenosis of less 
than 30%) was achieved in 100 % of patients. Within 30 days, 2 patients (8%) had a TIA 
and one patient suffered (4%) a non-disabling stroke that resolved completely within 
2 days. The 30-day-all-cause-mortality was 0%. The mean clinical follow-up time after 
CAS was 3.3 years (SD 2.3; range 0.3 to 11.0 years). Non-procedural cerebrovascular 
events occurred in four patients: one patient had a ipsilateral TIA (4%) and in 3 
patients a contralateral event (12%) occurred (table 2). The proportion without any 
cerebrovascular events during follow-up is shown in figure 1. Multivariate Cox- 
proportional hazard analysis showed no risk factor for ipsi -and contralateral incident 
cerebrovascular events.
Rates and degrees of restenosis are presented in table 3. No in-stent occlusion occurred. 
None of the restenosed vessels were symptomatic. In only one patient a restenting 
procedure was performed because of a rapid occurring instent restenosis of 90-99% 
with good post-procedural results (free from rerestenosis after 2 years). 
The length of the RT-CAS interval proved to be the most significant risk factor for 
restenosis at 3 months (RR 1.14; 95 % CI 1.0-1.3), meaning that each year elapsed since 
RT, the risk of restenosis increases with 14%.
Table 2. Clinical outcome of CAS for radiation induced stenosis. 
Clinical outcomes n= 24 (%)
Technical failure 0
Any periprocedural TIA, stroke or death (up to 30 days)
TIA
Non-disabling Stroke
Death
2 (8)
1 (4)
0 
Any non-procedural  TIA & strokes (disabling and non-disabling)
Ipsilateral
TIA
Contralateral
TIA
Disabling stroke
4 (16%)
1 (4)
1 (4) 
2 (8)
Any non-procedural deaths
Contralateral stroke*
Other vascular death **
Non-vascular death † 
7 (29)
1 (4)
2 (8)
4 (16)
* One patient died after the disabling stroke.
** Other vascular dead consisted of myocardial infarction and heart failure.
† Other causes of non-vascular dead consisted of breast cancer, pneumonia, car accident and 1 unspecified 
cause of dead.
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Table 3. Stent patency measured by duplex ultrasound at 3 months, 1 and 2 years follow-up.
Stent patency n (%)
Restenosis 3 months (n= 23)
0-49% 
50-69%
70-89%
90-99%
Occlusion
19 (83)
4 (17)
0
0
0
Restenosis 1 year (n=21)
0-49% 
50-69%
70-89%
90-99%
Occlusion
14 (67)
3 (14)
3 (14)
1 (5)
0
Restenosis 2 year (n= 17)
0-49% 
50-69%
70-89%
90-99%
Occlusion
10 (59)
4 (24)
1 (6)
2 (12)
0
Figure 1. Kaplan-Meier analysis showing the cumulative freedom from cerebrovascular events (TIA and 
stroke) at the ispilateral and contralateral side of CAS.
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Discussion
We report the long term outcome for patients with Carotid Angioplasty and Stenting 
(CAS) for symptomatic carotid stenosis after RT on the neck. These patients are at 
increased operative risk during carotid endarterectomy (CEA) and are excluded 
by large randomized intervention trials. In this high risk population we found that 
periprocedural CAS risks appear to be comparable to CAS in non-irradiated patients.16 
Disabling stroke or death within 30 days was 0%. Overall, the non-procedural 
proportion of ipsilateral incident cerebrovascular events in our study was low (4%) and 
only transient (one patient with TIA). The actuarial risk of any incident TIA and stroke 
was 16% after a median follow-up of 3.3 years. At 3 years follow-up this is comparable 
to other high risk surgical patients (those with coexisting conditions, such cardiac 
morbidity and a destructed neck anatomy). The recently completed SAPPHIRE study 
reported an overall stroke occurrence in 9% of patients at 3 years which is comparable 
to the 8% stroke occurrence in our cohort.17 The observed incident cerebrovascular 
events cannot be attributed to failure of the CAS procedure, since 3 out of 4 events 
occurred at the non-CAS side. The occurrence of new cerebrovascular events is most 
likely a reflection of high incidence of bilateral carotid disease after RT rather than a 
result of restenosis: almost 60% of our patients had a contralateral stenosis or occlusion 
of the carotid artery. 
Restenosis was apparent in 17%, 33% and 42% of patients at 3 months, 1 and 2 
years following CAS. None of these patients became symptomatic. These results are 
comparable to two cohort studies of CAS after irradiation: both studies show high 
restenosis rates of respectively 21% and 43% after a mean follow-up of 28 months 
(n=16 patients) and 14.4 months (n=23 patients).18,19 This high percentage of 
restenosis can be a result of overrating.20 DUS velocity criteria, e.g. PSV, correlate with 
angiographic percentages of stenosis in non-stented carotids. In CAS patients, DUS 
velocity criteria are not yet well established. One recent cohort study proposed new 
criteria for grading percentage of stenosis after CAS by ultrasound after comparison 
with the gold standard: angiography.21 In this study it was found that compliance and 
flow characteristics are much different when compared to non-stented arteries. New 
thresholds of velocity criteria for different degrees of intrastent stenosis were found 
much higher. It is conceivable that in our patient cohort, with fibrous and scarred 
necks, duplex application is even more difficult than in non-irradiated patient. Also, a 
contralateral occlusion (present in 25% of our patients) is known to overrate the degree 
of ipsilateral stenosis.22 We therefore advise to perform (CT- or MR-) angiography 
to confirm restenosis in case of symptomatic disease. In case of restenosis without 
symptoms it is warranted to carefully survey these patients by frequent DUS at intervals 
of 3 months to detect any progression of restenosis. 
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The study has limitations. First, we performed an observational study. Ideally 
comparison of CAS versus CEA is warranted to define the best treatment; however, 
such randomized trial is not feasible for this specific, relatively small cohort of patients. 
Second, DUS follow-up is not complete. This is due to the fact that our centers serve 
as tertiary referral hospitals and most patients will be followed by their referral 
physician. 
Despite of this, we consider strong elements of our study being a double-center, 
cohort study with 100% response rate and complete clinical follow-up.
The final decision how to treat a patient with radiation induced carotid stenosis should 
be individualized and based on several factors, including e.g. former neck operation 
and cardiovascular risk factors.  Also the time elapsed between RT and the primary 
cerebrovascular symptoms should be weighted, as in our study a longer time interval 
since RT proved to be negatively correlated with patency rates. Although we found a 
high rate of restenosis on DUS only 2 patients (8%) progressed to high grade (90-99%) 
stenosis. The long-term clinical follow-up results in our cohort are favorable i.e. no new 
strokes occurred at the ipsilateral stented carotid artery. Close surveillance of patency 
is necessary also for detection of contralateral stenosis that remains a risk factor for 
new cerebrovascular events.
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Background and introduction
Successful curative treatment for malignancies is increasingly available; additional 
attention must therefore be paid to prevent complications. One of these complications 
is radiation induced vascular side effects. These vascular side effects have been 
reported as early as 1899. Thereafter several studies reported the histopathological 
findings of radiation induced vascular disease.1,2 Endothelial swelling and proliferation, 
in combination with ischemia of the medial and adventitial layer due to damage 
of the vasa vasorum, leads to obliteration of the irradiated vessel and can cause 
thromboembolism.3 The latter plays an important role in the neurological sequelae in 
patients irradiated for head and neck malignancies.
The radiation induced vessel changes observed in patients and duplicated in animal 
models are similar to accelerated age-related atherosclerosis although restricted to 
the radiation portal. The vasculopathy is both time and dose dependent; however, 
Chung et al. did not find a specific relation between dosage and luminal narrowing at 
pre- and postradiation MR scans in patients irradiated for head and neck malignancies. 
In this study the minimum radiation dose inducing vessel narrowing was 40 Gy.4 The 
radiation-related vessel changes increase in time and appear to have a significant 
clinical effect i.e. transient ischemic attack or cerebral infarction in case of radiotherapy 
(RT) on the neck. In a retrospective study on the relative risk (RR) of stroke in patients 
younger than 60 years irradiated for head and neck malignancies we found a RR of 5.6 
of occurrence of stroke after RT on the neck.5 The incidence rates of cerebral infarctions 
in the normal population according to the Oxfordshire community stroke project are 
shown in table 1.6
Recently, Muzaffar et al. demonstrated that duplex ultrasonography of the intima-
media thickness (IMT) of the irradiated carotid artery showed progressive thickening 
of the IMT during the first 12 months after RT. Furthermore, they found this process to 
be continuing during the second year.7 In this study they estimated the acceleration of 
the normal process of atherosclerosis to be 21 fold greater than normal per year.  
IMT of the carotid artery is a reliable and independent predictor of cerebrovascular 
disease.8,9 In a large prospective, multicenter study, O’Leary et al. demonstrated that 
the RR of stroke is increased with the IMT (p<0.001). Moreover, in this study an increase 
of one standard deviation (0.20 mm) of IMT causes an increase of the risk of stroke of 
27% (adjusted for age, sex and other risk factors).
The use of HMG-coA reductase inhibitors (”statins”) or ACE-inhibitors can influence 
the mode of acceleration of atherosclerotic plaques.10,11 HMG-coA reductase 
inhibitors lower the LDL, VLDL-cholesterol and triglycerides concentration. Next 
to that, they increase the level of HDL-cholesterol. They diminish the acceleration 
of the atherosclerotic process by reducing the foamed macrophagic cells in the 
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atherosclerotic plaques. Furthermore, statins have a pleiotropic effect.12 Their action 
would be plaque stabilization by direct biological effects on the endothelial function, 
arterial wall and the biological promoters of plaque stabilization, meaning avoiding 
rupture or ulceration.13 The LIPID study group showed a significant declination in the 
mean arterial wall thickness in a group of cerebrovascular risk patients with normal 
cholesterol levels treated with pravastatin compared to a placebo in 4 years of follow 
up.10 Side effects of statin treatment occur only infrequent and are usually mild.14,15
In this study we want to investigate the efficacy of the HMG-coA reductase inhibitor, 
atorvastatin 20 mg in reducing the progression of radiation induced IMT-thickening. 
The effect will be studied in an open label multicenter clinical trial. The study group will 
be treated with atorvastatin 20 mg. The control group will not receive medication. The 
primary end-point is the difference in IMT before, 0.5 and 2 years after RT on the neck. 
The IMT of the carotid artery will be measured by duplex ultrasonography. This is a safe 
and non-invasive technique. The Spearman correlation between readers varies between 
0.75 tot 0.86 in the literature which indicates a high interobservers agreement.8,9 IMT-
measuring of the carotid artery is a reliable indicator of atherosclerosis and truly 
reflects the anatomical intima and media layer.16 Therefore this technique can be 
applied to document the process of atherosclerosis in time and measure intervention 
on atherosclerosis.17 
Furthermore, we will investigate whether inflammatory markers, which are known to 
increase during age-related athrosclerosis18,19, are upregulated during RT and whether 
they are influenced by treatment with an HMG-coA reductase inhibitor. The pattern of 
expression of these markers will provide more insight in the process of atherosclerosis 
after RT.  
 
Table 1. Adapted from Bamford et al.6 Rates / 1000 population/year
Age Male Female Total (rate)
< 45 7 11 18 (0.1)
45-54 11 6 17 (0.4)
55-64 54 33 87 (2.3)
65-74 93 74 167 (5.9)
75-84 89 100 189 (11.9)
85+ 19 48 67 (15.0)
Total 273 272 545 (1.3)
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Objectives of the trial
Primary objectives
1.   To investigate the effect of an HMG-coA reductase inhibitor, atorvastatin 20 mg, on 
the progression of  IMT of the carotid artery after RT in patients treated for head and 
neck tumors.
2.  To determine the change in IMT of the irradiated carotid artery in comparison 
with the unirradiated femoral artery and to document the impact of an HMG-coA 
reductase inhibitor on both arteries.
3.   To document any difference in the IMT of the bilateral carotid arteries in patients 
receiving an HMG-coA reductase inhibitor following unilateral irradiation to the 
neck.
4.   To document any changes in the pattern of inflammatory markers, i.e. c-reactive 
protein (CRP), intercellular adhesion molecule (ICAM), vascular cell adhesion 
molecule (VCAM-1) during RT and the following 2 years and to see whether this is 
influenced by an HMG-coA reductase inhibitor; atorvastatin 20 mg.
Secondary objectives 
To quantify the occurrence of cerebrovascular events (transient ischemic attack, 
amaurosis fugax and stroke) in patients irradiated on the neck after treatment with an 
HMG-coA reductase inhibitor in comparison to those receiving no further treatment.
End-points
1.  The primary end-point will be the mean change in IMT between the treated and 
non-treated group after 2 years of treatment.
2.  The second end-point will be the change in IMT between the irradiated carotid 
artery compared to the unirradiated femoral artery after treatment with an HMG-
coA reductase inhibitor
3.  The third end-point will be the rate of ischemic cerebral vascular accidents in both 
groups.
Patient selection criteria
Inclusion criteria
-   Patients older than 18 years with T1, T2 laryngeal carcinoma (N0-2, M0) are included. 
They will all be treated by RT with a curative option. 
-   Or patients with parotid carcinoma T1, T2 (N0-2, M0) are included if they will receive 
RT after conservative parotidectomy as post-operative treatment.
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-   Or patients with pleomorphic adenoma are included when they will be treated with 
RT in the postoperative course in case of tumor spill or incomplete resection. 
-   Or patients with oropharynx carcinomas T1, T2 (N0-2, M0) or hypopharynx carcinoma 
T1, T2 (N0-2, M0) are included. They will receive RT with a curative option. 
-   Or patients with non-Hodgkin lymphoma or M. Hodgkin are included when they 
will be treated with RT on the neck.
-  Written informed consent.
Exclusion criteria
-  Patients with a history of cerebrovascular disease.
-  Patients who are pregnant or breast-feeding.
-   Patients who are receiving ongoing treatment with an HMG-coA reductase 
inhibitor.
-  Life expectancy < 2 years.
-   Patients who are not able to give informed consent because of receptive language 
difficulties, intellectual decline or psychiatric illness.
-   Patients taking inhibitors of cytochroom P450 i.e. ciclosporine, fibrates, macrolidic 
antibiotics, azol micotica, nicotinic acid and verapamil.
-   Patients with active liver disease or high levels of serum transaminases (>3 times 
the upper limit)
-  Patients with 5  times normal level of creatine phosphokinase.
-   Patients with hypercholesterolemia i.e. serum cholesterol > 7.0 mmol/l. Patients will 
be referred to their general practitioner in order to start treatment.
Number of patients
A power analysis (see sample size) revealed that a minimum number of 151 patients is 
needed for both groups. Per year, at the Netherlands Cancer Institute, approximately 
166 patients are irradiated in case of laryngeal carcinoma, parotid tumor, oropharynx 
and hypopharynx carcinoma. At the Radboud University Nijmegen Medical Center 
around 150 patients are irradiated for these indications per year. In total an expected 
number of 316 patients will be eligible for the study. Taking into account a refusal or 
ineligibility percentage of 50%, annually 158 patients could be included. Therefore an 
inclusion period of 2 years is determined.
Trial Design
-  The trial will be conducted as an open-label, multicenter clinical trial.
-  The trial will be conducted in three centers i.e. the Radboud University Nijmegen 
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Medical Center, Nijmegen and the Netherlands Cancer Institute/ Antoni van 
Leeuwenhoek Hospital, Amsterdam and the University Medical Center Maastricht, 
Maastricht.
-  Patients will be equally randomized in two groups. The study group will receive oral 
daily administration of an HMG-coA reductase inhibitor i.e. atorvastatin  20 mg. The 
control-group does not receive any medication.
-  Stratification will be done according to tumor type, age, chemotherapy, and 
cerebrovascular risk factors i.e. hypertension, smoking, atrial fibrillation and diabetes 
mellitus.
-  Before RT patients are stratified and randomized in equal groups and enrolled to 
the study.
- Before RT is given baseline measurements will be performed.
Figure 1. Randomization and treatment protocol
  5. Parotid carcinoma or pleomorphic 
adenoma patients 
 
1. Larynx carcinoma patients 
2. Hypopharynxcarcinoma patients 
3. Oropharynxcarcinoma patients 
4. Hodgkin or non-Hodgkin lymphoma 
patients 
 
Tumor resection 
 
Randomization and stratification 
 
Group 1 (non-treatment group) 
 
Group 2 (treatment group) 
Atorvastatin 20 mg 
 
Radiotherapy 
 
Evaluation t = 0.5, 2 years 
 
Radiotherapy 
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Therapeutic regimens, expected toxicity, dose modifications
Study medication
An HMG-coA reductase inhibitor atorvastatin; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-
4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, is 
used as study-medication. The tablet is film coated. HMG-coA reductase inhibitors are 
prescribed in case of hypercholesterolemia. They reduce the total- and LDL cholesterol 
level and increase the HDL-cholesterol. They are know to reduce the incidence of 
cardiovascular morbidity and therefore prescribed as secondary prevention in case of 
high risk patients.
In case of swallowing difficulties the tablet can be  crushed.
Treatment design 
Eligible patients will be screened according to the specifications described in 
paragraph “Patient selection criteria”. Patients are equally randomized in each group 
(treatment versus non-treatment). Two weeks before RT is started the study group will 
start treatment with atorvastatin 20 mg.
Group 1 (non-treatment group)  
These patients will not receive medication. They will be reviewed for follow-up at the 
same time-schedule (see “during treatment t=5 and t=6”) as the treatment-group. 
Clinical and laboratory studies will be performed during RT (5 weeks after the start of 
the study, i.e. 3 weeks after the start of RT) and at the same time of ultrasonography 
measurements i.e. baseline, 0.5 and 2 years after treatment (see “during treatment t=5 
and t=6”).
Group 2 (treatment group)
The treatment group will receive 20 mg of atorvastatin daily. The patients will start with 
the study medication two weeks before RT starts. Clinical and laboratory studies will 
be performed at the same time as the ultrasonography measurements i.e. baseline, 0.5 
and 2 years after treatment and during RT (see “during treatment t=5 and t=6”).
Toxicity
Side effects are usually mild and temporally. Side effects described in literature which 
occur frequently (> 1%- < 10 %) are  dyspepsia, nausea, abdominal pain, insomnia, 
and headache. Rare (> 0.1%- < 1%) reported side effects consist of myalgia, myopathy, 
rash and urticaria. Very rare (< 0.1%) occurring side effects are hepatitis, myositis, 
rhabdomyolysis, edema of the face, angioedema, vasculitis, and lupes-like reactions. 
In few patients (< 2%) liver-transaminases were elevated more than 3 times the upper 
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limit. Seldom, elevated levels of creatine phosphokinase were reported. Atorvastatin 
can interact with cytochroom P450 (cyp3A4) inhibitors like claritromycine, delavirdine, 
diltiazem, verapamil, erytromycin, itraconazol, ketaconazol, nefazodon and protease 
inhibitors. Patients who are receiving ongoing treatment with digoxine should be 
frequently evaluated.  
Off trial
Patients who will receive cytochroom P450 inhibitors. They will be withdrawn from the 
study. Patients with recurrent disease who will need further treatment in the head and 
neck region will be censored from further analysis. Patients who are lost to follow-up 
or die will also be censored from further analysis.
Patients who suffer from a cerebrovascular event (i.e. a transient ischemic attack, 
amaurosis fugax or stroke) during the study will be censored from further analysis also 
and they will be referred to a neurologist for further management. 
Clinical evaluation, laboratory tests and follow-up
General 
At baseline  (i.e. before RT starts), at 0.5 and 2 years after RT patients will be evaluated 
by duplex ultrasonography. At the same time as duplex ultrasonography is performed 
and 5 weeks after the start of the study (i.e. 3 weeks after the start of RT) physical 
examination and laboratory test will be repeated.
Before treatment (time(t)=1)
Patients are enrolled in the study with the diagnosis T1-2, N0-2, M0 laryngeal 
carcinoma, pleiomorphic adenoma, T1-2, N0-2, M0 parotid carcinoma and T1-2, N0-2, 
M0 oropharynx and hypopharynx carcinomoma.  Patients with laryngeal carcinoma, 
oropharynx and hypopharynx carcinoma will will receive baseline measurements 
before RT starts. Patients with a parotid tumor (i.e. pleomorphic adenoma or 
parotid carcinoma) will receive baseline measurements after performing superficial 
parotidectomy. 
Baseline measurements performed before radiotherapy are: 
1. Physical examination
2. Screening for cerebrovascular risk factors
3. Laboratory testing; baseline blood test and inflammatory markers
4. Duplex ultrasonography
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1. Physical examination and medical history
 - Routine physical examination (including weight, length)
 - Performance status
 -  Systolic and diastolic blood pressure. The blood pressure is measured at the right 
arm with the patient in sitting position. 
 - Evaluation of medication 
2. Screening cerebrovascular risk factors
 - Diabetes Mellitus (see also laboratory test)
 - Hypertension (RR> 160/95). 
 - Smoking; 
	 	 •	 Never	smoked,
	 	 •	 	Former	smoker	(those	who	stopped	smoking	before	participation	in	the	study	
for at least 3 years).
	 	 •	 	Current	smoker	(those	who	continued	smoking)	or	stopped	smoking	less	than	
3 years ago.
 - History of cardiovascular disease
 - Family history of cardiovascular disease
3. Laboratory test
 -  Baseline blood test: Hemoglobin, white blood cells, neutrophils, platelets, 
renal and hepatic function, lipid profile and homocystein after overnight fast 
(cholesterol, HDL-cholesterol, LDL-cholesterol, triglicerides, lipoproteins), 
creatine phosphokinase, glucose, thyroid stimulating hormone and thyroxine. 
 -  Inflammatory markers: CRP, intercellular adhesion molecule (ICAM), vascular cell 
adhesion molecule (VCAM-1). The CRP will be measured according to a standard 
laboratory procedure in both the Netherlands Cancer Institute and the Raboud 
University Nijmgen Medical Center. The ICAM and VCAM-1 will be measured by 
L. Dorresteijn at the Laboratory of the department of Neurology at the Radboud 
University Nijmegen Medical Center. This will be performed by commercial 
available ELISA-methods.
4. Duplex ultrasonography
 -  Patients with laryngeal carcinoma and hypopharynx carcinoma:
   Duplex ultrasonography of both carotid arteries is performed with a 7.5 MHz 
Linear array transducer using a duplex scanner as described by Pignoli et al..20 In 
supine position, at a marked point (the isocenter, i.e. a part of the carotid artery 
which receives > 95% of the irradiated doses, defined in cm distance from the 
mandibular angle) and 1 cm above and below the isocenter the far wall of the 
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common or internal carotid artery is assessed. Also the far wall of the femoral 
artery is assessed by the same technique. Images are freezed on video by the 
reader who is blinded for clinical information. The IMT is defined as the distance 
between the intima and media double line pattern and expressed in millimeters. 
From the videotape, the frozen images are digitized and displayed on the 
screen of a personal computer using additional dedicated software.21 Computer 
software calculates the mean values as well as the maximum values for IMT. This 
procedure is obtained for both sides. 
 -  Patients with parotid tumors and oropharynx carcinomas:
   The same technique as described above is used i.e. both irradiated as well as not-
irradiated carotid artery is measured. The measuring point is the isocenter and 1 
cm above and below the isocenter. 
Randomization and stratification (t=2)
All eligible patients are equally randomized in two groups. Randomization will be 
centrally performed  according to the Netherlands Cancer Institute procedures  (see 
statistical considerations). Patients who enter the study are stratified by using a 
minimization technique (see stratification criteria).
Treatment (t=3)
Patients who are randomized in group 2 will receive daily administration of an HMG-
coA reductase inhibitor, atorvastatin 20 mg two weeks before starting RT. The treatment 
will continue during the study period i.e. 2 years. 
Radiotherapy  (t=4)
-  All patients who are enrolled in the study will receive RT according to the standard 
treatment protocol. Patients with laryngeal carcinoma and hypopharynx carcinoma 
receive RT with opposed lateral fields. Both carotid arteries are within the RT-portal. 
-  Patients with pleomorphic adenoma, parotid carcinoma and oropharynx carinoma 
receive radiotherapy unilaterally with a wedge pair technique as post-operative 
treatment. 
-  Before and during RT the radiation status is screened
	 •	 Dose	of	RT		
	 •	 Fractionation	
	 •	 	Side	of	RT	(bilateral	or	unilateral)
	 •		 Length	of	the	carotid	artery	within	the	RT-portal.
	 •		 	Percentage	 of	 dose	 to	 the	 carotid	 artery	 at	 the	 marked	 points	 (i.e.	 isocenter	
and 1 cm above and below). This is calculated by CT simulation at the time of 
radiotherapy planning
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-  During RT (t=4) patients will be screened for baseline blood test, inflammatory 
markers and performance status at 3 weeks after the start of RT.
During treatment (t=5 and t=6) 
Patients will be evaluated at 0.5 and 2 years after start of treatment with an HMG-coA 
reductase inhibitor by 
	 •	 Physical	examination
	 •	 Tumor	status
	 •	 Laboratory	testing
	 •		 Ultrasonography
After completion of the study
After completion of the study the results will be evaluated. However, the medical 
supervision will continue in order to document cerebrovascular events in both groups. 
Until the results are available patients who are on medication are advised to continue 
this. Patients will be monitored once a year, and after a follow-up period of 5 years IMT-
measurement is repeated.
Summary table
t=1
Screening
Pre-study
t=2
Randomization 
& Stratification
t=3
Start 
Treatment
t=4
Radiotherapy
t=5
0.5 year
t=6
2.0 years
Medical history x
Performance state x x x x x
Tumor status x x x
Medication x
Cerebrovascular 
risk factors
x
Physical 
examination
x x x x x
Baseline blood test x x x x
Inflammatory 
markers
x x x x
Ultrasonography x x x
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Criteria of evaluation
End-points
Intima-media thickness
-  The IMT will be measured at a three marked points for both left and right carotid 
artery. In patients with laryngeal and hypopharynx carcinoma measurements will 
be performed at the isocenter, 1 cm above and below the isocenter. 
-  In patients with parotid tumors and oropharynx carcinomas the IMT will be measured 
at the isocenter, 1 cm above and below the isocenter and repeated for both sides. 
-  The primary endpoint is the mean change (of the three measurements) of the IMT. 
This is calculated by the difference of IMT at a given time point (t=5, t=6)  compared to 
the baseline measurement. The mean change of the IMT is expressed in millimetres. 
Furthermore the difference between the change in IMT of the carotid artery and the 
femoral artery is calculated.
Cerebrovascular accidents
-  In case of an ischemic cerebrovascular accident patients are evaluated by a 
independent neurologist. The type of the cerebrovascular accident is assessed as 
well as the vascular territory and the affected cerebral hemisphere. 
-  The amount of ischemic cerebrovascular accidents is assessed.
Stratification criteria
Patients are stratified before enrolling into the study. Stratification criteria are type of 
tumor i.e. laryngeal carcinoma, parotid tumor, oropharynx, hypopharynx carcinoma, 
Hodgkin and non-Hodgkin lymphoma. Stratification is also performed according 
to age, chemotherapy and cerebrovascular risk factors, which are known to have 
an impact on the IMT as smoking versus non-smoking, hypertension versus non-
hypertension and  diabetes mellitus versus non-diabetes mellitus. Also stratification 
is performed for patients with atrial fibrillation. Treatment assignment will be made 
using a minimization technique.
Statistical considerations
Sample size
From previous studies the increase of IMT in four years is estimated to be around 0.05 
mm in non-irradiated patients. In irradiated patients this increase is accelerated 15-
20 times. We expect to detect a difference of -0.150 mm after 2 years of treatment. 
A sample size of 151 patients in each group will have a power of 90% to detect a 
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difference in means of -0.150 (the difference between a group 1 mean, µ1, of 0,150 and 
a group 2 mean, µ2, of 0.000) assuming that the common standard deviation is 0.400 
mm22 using a two group t-test with a 0.05 two-sided significance level. 
Randomization and stratifications
Patients will be centrally randomized. A minimization technique will be used for 
random treatment allocation by the Netherlands Cancer Institute (Dept. of biostatistics, 
O. Dalesio). 
Adverse Event
Adverse event (AE) – definition: Any untoward medical occurrence in a subject 
participating in this study. An AE does not necessarily have causal relationship with the 
study drug or RT. For this study all AEs will be reported to the study coordinators. AEs 
will be collected from the time the subject signs the informed consent. They include 
any change from the subject’s pretreatment (screening) condition as symptoms 
or physical findings. An abnormal laboratory value may be considered an AE if the 
identified abnormality leads to any type of intervention, e.g. withdrawal of the study 
treatment, withholding treatment pending additional investigations.    
AE criteria will be graded on a 3-point scale (mild – moderate – severe).
Mild     - discomfort noticed, no disruption normal daily activity
Moderate  - discomfort sufficient to reduce or affect daily activity
Severe   - incapacitating, with inability to work or perform daily activity
Patients who stop the study medication because of intolerance will go off the study. 
Serious adverse events
Serious Adverse Events (SAE) are defined as follows according GCP-rules:
	 •	 results	in	death
	 •	 life	threatening
	 •	 requires	inpatient	hospitalization	or	prolongation	of	existing	hospitalization
	 •	 results	in	persistent	or	significant	disability/incapacity,	or
	 •	 is	a	congenital	anomaly/birth	defect
All SAEs, irrespective of relationship to the study treatment must be reported to the 
trial office at the NCI/AvL as soon as possible, but no later than one working day. The 
SAE report should include the investigator’s assessment of causality. If follow-up 
information changes the investigator’s assessment of causality, this should be noted 
on the follow-up SAE form. SAEs occurring within 30 days after discontinuation of the 
study treatment should be reported.
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Ethical considerations
Patient protection
The responsible investigator will ensure that this study is conducted in agreement 
with either the Declaration of Helsinki (Tokyo, Venice, Hong Kong and Somerset West 
amendments) or the laws and regulations of the country, whichever provides the 
greatest protection of the patient.
The protocol will by approved by the Local, Regional or National Ethics Committees.
Subject identification
The name of the patient will not be asked nor recorded at the Data Center. A sequential 
identification number will be automatically attributed to each patient registered in the 
trial. This number will identify the patient and must be included on all case report 
forms. In order to avoid identification errors, patients initials (maximum of 4 letters), 
date of birth and local chart number (if available) will also be reported on the case 
report forms.
Informed consent
All patients will be informed of the aims of the study, the possible adverse events, the 
procedures and possible hazards to which he/she will be exposed, and the mechanism of 
treatment allocation. They will be informed as to the strict confidentiality of their patient 
data, but that their medical records may be reviewed for trial purposes by authorized 
individuals other than their treating physician.  It will be emphasized that the participation 
is voluntary and that the patient is allowed to refuse further participation in the protocol 
whenever he/she wants. This will not prejudice the patient’s subsequent care. Documented 
informed consent must be obtained for all patients included in the study before they are 
registered or randomized at the Netherlands Cancer Institute Data Center. This must be 
done in accordance with the national and local regulatory requirements.
Administrative responsibilities
The study coordinator
The study coordinator (in cooperation with the Data Center) will be responsible for 
writing the protocol, reviewing all case report forms and documenting his/her review 
on evaluation forms, discussing the contents of the reports with the Data Manager 
and the Statistician, and for publishing the study results. He will also generally be 
responsible for answering all clinical questions concerning eligibility, treatment, and 
the evaluation of the patients.
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Study coordinators
Drs L.D.A. Dorresteijn 
Address : Radboud University Nijmegen Medical Center, Reinier Postlaan 4, Nijmegen.
Phone : +31 – 24 – 361 88 60
Fax  : +31 – 24 – 354 11 22
e-mail : L.Dorresteijn@neuro.umcn.nl
Dr F. Hoebers
Address : Netherlands Cancer Institute, Plesmanlaan 121,1066 CX, Amsterdam
Phone : +31 – 20 – 512 17 14
Fax   : +31 – 20 – 669 11 01
e-mail  : F.hoebers@nki.nl 
Dr  W. Boogerd
Address : Netherlands Cancer Institute, Plesmanlaan 121,1066 CX, Amsterdam
Phone : +31 – 20 – 512 25 70
Fax  : +31 – 20 – 512 25 72
e-mail : W.Boogerd@nki.nl
The Netherlands Cancer Institute Data Center
The Data Center will be responsible for reviewing the protocol, collecting case report 
forms, controlling the quality of the reported data, and generating reports and analyses 
in cooperation with the study coordinator. 
Publication and authorships
All information generated by this study is full property of the investigators as mentioned 
in the writing committee. Original subject records are audited and reviewed by the 
study coordinators to verify the accuracy of data and protocol adherence. None of this 
information may be used for publication or presentation without the written approval 
of the study coordinator. 
Trial Insurance 
For this study with a low-risk profile the Netherlands Cancer Institute is insured by 
Medirisk.
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Summary
Cancer affects one-third of the male and a quarter of the female population in the 
Netherlands. With increasing survival rates due to better treatment, cancer is becoming 
a chronic disease. In view of this increased survival, it has become exceedingly 
important to focus on long-term treatment-related complications. Knowledge of late 
complications may not only be of importance for modifying cancer treatment regimens 
but also to consider possible preventive strategies for these late complications at the 
time of cancer diagnosis and treatment. Late complications consist e.g. of second 
malignancies and cardiovascular disease. Among the latter, stroke is a major cause of 
long term disability that affects patients’ cognitive and functional outcome.1,2
 
Aims of the studies described in this thesis are to assess incidence and risk factors for 
radiation induced cerebrovascular disease, and to study outcome and prevention of 
radiation induced carotid disease.
In chapter 2.1 we present the incidence of ischemic stroke in patients irradiated on the 
neck for head and neck tumors: laryngeal carcinoma (n=162), pleomorphic adenoma 
(n=114) and parotid carcinoma (n= 91). Patients were treated with local radiotherapy 
(RT) on the neck at age below 60 years and followed for a median of 7.7 years (3011 
person years). Follow-up information was gathered by medical record review at the 
Netherlands Cancer Institute (NKI/AVL). If follow-up information was incomplete, we 
collected data on stroke and cerebrovascular risk factors from the patient’s general 
practitioner. 
In our population we found an increased risk of ischemic stroke of 5.6 (95% confidence 
interval (CI) 3.1-9.4) when compared to the general population, and adjusted for age 
and sex. Each patient group exhibited an increased risk of ischemic stroke: patient 
with laryngeal carcinoma had a relative risk (RR) of 5.1 (95% CI 2.2-10.1), patients with 
pleomorphic adenoma had a RR of 5.7 (95% CI 1.5-14.5) and parotid tumor patients 
a RR of 8.5 (95% CI 1.0-30.6). Analysis of other risk factors for stroke showed that 
hypertension and diabetes mellitus caused a further increase of the RR after RT. Stroke 
risk continued to increase with progression of time: after 10-years of follow up the RR 
increased to 10.1. The 15-year cumulative risk of stroke was 12%. 
In chapter 2.2 we describe treatment specific risk and stroke of cerebrovascular events 
(stoke and transient ischemic attack (TIA)) in all 10-year survivors (n=4414) of the Late 
Effect Breast Cancer Study. The Late Effect Breast Cancer Study is a retrospective cohort 
study consisting of 7425 1-year survivors of breast cancer, treated from the 1970s 
through the 1980s in the two major cancer centers in the Netherlands (i.e. NKI/AVL and 
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DDHK).  Overall we found that the risk of stroke was decreased by 25% in comparison 
with the general female population. Patients irradiated at the supraclavicular area 
(encompassing the common carotid artery) and/or the internal mammary chain 
(encompassing the aortic notch) did not experience a higher risk of stroke (hazard ratio 
(HR) 1.0; 95% CI 0.7-1.6) or TIA (HR 1.4; 95% CI 0.9-2.5) in comparison with patients who 
did not receive RT or were irradiated on fields other than supraclavicular or internal 
mammary chain. Significant increased risks of stroke were found in women who had 
received hormonal treatment (tamoxifen), and in women who had hypertension or 
hypercholesterolemia, with HR of 1.9, 2.1, and 1.6, respectively. From these data we 
may conclude that long-term survivors of breast-cancer experience no increased 
risk of cerebrovascular disease compared with the general population. Hormonal 
treatment is associated with an increased risk of stroke, while radiation fields including 
the proximal part of the common carotid artery do not increase the risk of stroke 
compared to other fields.
In chapter 2.3 we studied the clinically verified incidence of stroke and TIA in a cohort 
of 5-year Hodgkin’s lymphoma survivors treated at age < 51 years (n=2201). After a 
median follow-up period of 17.5 years, 96 patients developed cerebrovascular disease: 
55 a stroke, 31 a TIA, and 10 patients both a TIA and a stroke. Of the 65 strokes, 57 were 
ischemic, 7 were hemorrhagic (incl. 2 subarachnoid hemorrhages), and in 1 case the 
type could not be verified. Most ischemic events were of large-artery atherosclerotic 
(36%) or cardio-embolic (24%) subtype. 
When compared to a sex and age-matched population, we found that Hodgkin’s 
lymphoma survivors have a 2.2-fold (95% CI 1.7-2.8) increased risk of stroke and a 3-fold 
(95% CI 2.2-4.2) increased risk of TIA. The overall cumulative incidence of TIA and stroke 
was 7% at 30-years of follow up. There was a significant trend of increasing risk with 
younger age at first treatment. Irradiation on the neck and mediastinum appeared to 
be an independent risk factor for the occurrence of ischemic cerebrovascular disease. 
Furthermore, we found that concurrent cardiac disease increased the subsequent risk 
of stroke and TIA by 2-fold.
In chapter 3.1 we address the question whether the increased incidence of stroke in 
patients irradiated on the neck for head and neck tumor is related to life style habits 
of smoking and drinking in these particular patients, or to irradiation to the carotid 
area. In case of unilateral irradiation, the contralateral unirradiated carotid artery can 
serve as an internal control. In this way we could eliminate all other risk factors and the 
difference can be ascribed to the effect of RT on the vascular tissue. We included 42 
consecutive patients who were treated with unilateral irradiation for parotid tumors 
(n= 18 parotid carcinoma, n=24 pleomorphic adenoma). Intima-media thickness (IMT) 
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was assessed by duplex ultrasonography. The median age at tumor diagnosis and 
radiation treatment was 47.4 years. The median interval between irradiation and IMT-
measurement was 9.8 years (range 3.4 to 27.2 years).
Overall, the irradiated side exhibited a significantly increased IMT of 1.13 mm compared 
to the unirradiated side (IMT=0.83). The mean difference in IMT was 0.30 mm (95% 
CI 0.03-0.57, p= 0.031). Stratification for the time interval from irradiation and IMT-
measurement showed that patients treated less than 10 years ago did not show a 
significant IMT-difference, whereas the mean IMT difference was 0.67 mm (p=0.007) 
if the post-irradiation time interval exceeded 10 years. A linear relation was apparent 
between the IMT-difference and the duration of the post-irradiation time interval.
We concluded that irradiation on the neck was a significant risk factor for increase in 
IMT. 
In chapter 4.1 we present the outcome of patients who underwent Carotid Angioplasty 
and Stenting (CAS) for radiation-induced stenosis of the carotid artery. CAS might be a 
preferable treatment modality for symptomatic carotid stenosis as it bypasses carotid 
endarterectomy that is associated with increased operative risks in former irradiated 
and operated neck patients. We followed a cohort of 24 patients who underwent CAS 
for symptomatic carotid stenosis after irradiation on the neck (mean time interval 
between RT and CAS 13 years). After a mean follow-up of 3.3 years (range 0.3-11.0 
years), 1 patient developed a TIA (4%) at the ipsilateral CAS-side. In 3 patients (12%) 
a new cerebrovascular event occurred at the contralateral side (1 TIA and 2 ischemic 
strokes). Restenosis, assessed by duplex ultrasonography, was apparent in 17%, 32% 
and 42% at respectively 3 months, 1 and 2 years although none of the patients with 
restenosed vessels became symptomatic. We concluded that CAS is a safe treatment 
modality and is effective in the prevention of new cerebrovasular events.
In chapter 5.1 we describe the design of a currently ongoing multicenter, randomized, 
controlled trial on the effect of a statin on the progression of the IMT induced by 
radiotherapy. The radiation-related vessel changes increase in time and appear to have 
a significant clinical effect i.e. TIA or ischemic stroke in case of irradiation on the neck. 
It is now beyond question that irradiation causes increase of the IMT. This is already 
apparent within the first 12 months after irradiation and seems to progress measurably 
during the second year.
The aim of the study is to investigate the efficacy of the HMG-coA reductase inhibitor, 
atorvastatin 20 mg, in reducing the progression of radiation induced IMT-thickening. 
The study is an open label multicenter clinical trial with a treatment group and control 
group. The treatment group receives atorvastatin 20 mg, at the start of RT whereas 
the control group does not receive medication. The primary end point is the mean 
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change in IMT between the treatment and control groups after 2 years of treatment. 
The secondary objective is to compare the occurrence of cerebrovascular events (TIA, 
amaurosis fugax and ischemic stroke) between the two study groups. In addition, in 
both study groups vascular inflammatory factors are assessed.
Patients, older that 18 years, are included before undergoing irradiation to the neck with 
curative intention for a larynxgeal carcinoma (T1 and T2), a parotid tumor (pleomorphic 
adenoma or carcinoma), a oropharynx carcinoma (T1, T2), a hypopharynx carcinoma 
(T1, T2) or a lymphoma in case of Hodgkin’s lymphoma. The IMT of the carotid artery is 
measured by duplex ultrasonography before irradiation, at 6 months and 2 years after 
irradiation. A power calculation determined that a minimum number of 151 patients is 
required per group (total of 302 patients) for the trial to reveal a significant difference 
of 0.150 millimeters in IMT after 2 years of treatment. The study was approved by 
the ethics committees of the three Dutch medical institutions (NKI/AVL, UMCN, and 
UMCM). The number of patients included from March 2003 to October 2008 was 106 
patients. 
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General discussion
Radiation induced stroke
We studied three different cohorts of tumor survivors in order to evaluate the impact 
of local irradiation on the carotid artery and the occurrence of stroke. The first study, 
which is described in chapter 2.1, showed that head and neck cancer patients 
(laryngeal carcinoma, parotid carcinoma and pleomorphic adenoma) harbor a strongly 
increased risk of (ischemic) stroke. This finding is in line with other studies reporting on 
the incidence and risk of stroke in head and neck cancer patients (table 1).3,4
  
Table 1. Comparison of different studies on the risk of stroke in head and neck cancer patients
Dorresteijn et al. Hayes et al.3 Smith et al.4
Year of publication 2002 2002 2008
No. of patients 367 413 6,862
Relative risk or Hazard ratio 5.6 (95% CI 3.1-9.4) 2.1 4.4  
Actuarial incidence 12% (at 15 years) 12% (at 5 years) 19% (at 5 years)
Mean/median age 49 < 80 (not further 
defined)
76 (+/- 7)
Younger patients  
(<65) excluded 
Median age at stroke 63 NR* NR
Median follow up (years) 7.8 NR 2.4
 *NR: not reported 
With respect to the relative risk (RR) of stroke, our patient group carries the highest 
RR. This might be due to the fact that we included a young cohort of head and neck 
tumor patients (median age at diagnosis 49 years) with corresponding low expected 
stroke rates (observed 14, expected 2.5; RR 5.6, chapter 2.1) The difference in age at 
RT (i.e. median age 49 years within our cohort vs. < 80 years and 76 years, respectively, 
in the two other cohorts) is likely responsible for the observed difference in actuarial 
stroke incidence (12% at 15 years, and respectively 12% and 19% at 5 years, table 1), 
indicating that stroke risk increases with age.
The same trend for increased risk of stroke was observed within the cohort of 
Hodgkin’s lymphoma survivors (chapter 2.3). Overall, we found an increased risk of 
stroke of 2.2. This finding is corroborated by the Childhood Cancer Survivor Study 
(CCSS) that presented self-reported incidence and risk factors for stroke in childhood 
Hodgkin’s survivors (RR 4.32, 95% CI 2.01-9.29).5 The main explanation why the CCSS 
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reported higher stroke risk is probably reflected by the difference in data acquisition: 
the CCSS gathered information by questionnaires to the patients themselves, whereas 
we collected the stroke information from the treating neurologist. In addition, the 
age at treatment in the CCSS cohort was younger than in our study population (<21 
years vs. <51 years). Also in Hodgkin’s lymphoma survivors, radiation to the neck and 
mediastinum proved an independent risk factor for ischemic stroke. 
In both our cohort studies (chapter 2.1 and chapter 2.3), young age at tumor 
diagnosis was found to be a detrimental factor: head and neck cancer patients treated 
with RT at age before 50 years harbor a RR of stroke of 9.8 (95% CI 3.2-22.9). Survivors 
of Hodgkin’s lymphoma who were treated at young age (≤ 20 years) have a RR of 3.8 
(95% CI 1.6-7.4). 
Contradictory results
Contrary to what we expected, in the third study (chapter 2.2), we found an overall 
decreased risk of stroke in 10-year survivors of breast cancer (RR 0.8; 95% CI 0.6 - 0.9). 
We had anticipated finding, in line with our other observations, an elevated stroke 
risk as radiation treatment encompasses the supraclavicular lymph nodes, and 
thereby also the proximal part of the common carotid artery (chapter 2.2 figure 1). We 
attributed this lower risk to several factors. First, breast cancer patients may modulate 
their cerebrovascular risk factors from the time of breast cancer diagnosis: e.g. they 
may opt for more exercise or a healthier diet and thereby reducing overweight.6,7 
Even if the latter was also the case in our study within head and neck cancer patients 
(chapter 2.1), with a much shorter follow-up time in this group, risk modulation was 
not apparent (median follow up time 7.8 years versus 17.7 years within the breast 
cancer survivors).  Second, the risk profile for breast cancer (i.e. late menopause) could 
be protective against (cerebro-)vascular disease.8,9 Finally, the supraclavicular radiation 
field encompasses significantly smaller parts of the carotid artery than irradiation fields 
for head and neck patients and Hodgkin’s lymphoma patients (chapter 2.3 figure 1 vs. 
chapter 2.2 figure 1).
On the other hand, hormonal treatment in breast cancer patients did increase stroke 
risk (HR 1.88; 95% CI 1.28 – 2.75). This finding is corroborated by others: Bushnell and 
Goldstein showed an elevated risk of ischemic stroke (RR 1.82; 95% CI 1.41 - 2.36).10
Stroke risk after breast cancer has also been investigated by others who, in contrast to 
our finding, reported elevated stroke rates. Recently, Jagsi et al. found a non-significantly 
elevated risk of stroke (RR 1.74; 95% CI 0.94 - 2.37) in patients with early breast cancer 
after a median follow-up of 6.8 years.11 And in a large population-based study (median 
follow-up 5.4 years), Nilsson et al. found that breast cancer patients had an overall 
RR of stroke of 1.12 (95% CI 1.07 - 1.17) compared with the general population,12 but 
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increased risk was especially found during the first year after diagnosis (RR 1.22; 95% CI 
1.06 - 1.39). Possibly, the increase rate during the first year was caused by tumor-related 
coagulation disorders.13,14 As we studied only those patients who survived more than 
10 years, acute or early occurring strokes (i.e. those strokes that occur within the first 
time interval after cancer diagnosis and during treatment) were beyond the scope of 
our study.
Mechanisms underlying late occurring radiation induced stroke
The pathogenesis of radiation induced stroke has been studied during the last two 
decades. From animal models we have learned that already in the acute phase 
endothelial damage appears after irradiation on large arteries.15 Endothelial cell 
activation and damage probably leads to a cascade of inflammatory reactions16,17 
that can result in the proliferation of the endothelial (i.e. intima) layer, fibrosis of the 
media layer, and obliteration of the vasa vasorum in the adventitia layer.18 There is 
also evidence that radiation induces prothrombotic effects which increase platelet 
adherence and thrombus formation in irradiated capillaries and arteries.19,20 The 
combination of these changes will eventually lead to plaque formation and narrowing 
of the arterial lumen. We hypothesize (chapter 5.1) that the first hit, i.e. the endothelial 
damage, may be prevented or at least be diminished by statin treatment. The presumed 
action of statins in normal age-related atherosclerosis is plaque stabilization by direct 
biological effects on the endothelial function and a slowing-down of the acceleration 
of the atherosclerotic process by reducing the foamed macrophagic cells in the 
atherosclerotic plaques.21,22
Intima and media thickness (IMT), the inner arterial wall, can be reliably studied by 
duplex ultrasonography.23-25 We and others have shown that unilateral irradiation 
causes significant increase of the IMT compared to the non-irradiated side (chapter 
3.1).26 The incidence of significant carotid stenosis on the irradiated side of the neck 
is also higher than on the contralateral side. The risk of IMT enhancement and carotid 
artery stenosis increases both with a longer time interval after RT.26,27 We hypothesize 
that the increased risk of stroke is associated with the enhanced IMT and the consequent 
carotid artery stenosis. In general, carotid artery stenosis is one of the main causes of 
stroke.28 
Another possible mechanism of stroke after irradiation is by cardio-embolism. To 
our best knowledge, we were the first to report on stroke risk in relation to cardiac 
disease after mantle field irradiation: in patients with RT-induced cardiac disease, the 
subsequent risk of stroke and TIA was increased by 2-fold during follow up (chapter 
2.3). Hodgkin’s lymphoma survivors have an increased risk of radiotherapy-related 
Chapter 6
136
cardiovascular disease like myocardial infarction and valvular dysfunction.29-31 It is 
possible that the increased risk of cardiac disease and the subsequent risk of cardio-
embolisms also explains why in our population stroke rates are increased whereas 
IMT-increase of the carotid artery and stenosis rates after mantle field irradiation are 
not as prominent as those observed within head and neck patients. Martin and others 
showed that 14 lymphoma patients irradiated on one side of the neck with relatively 
low dose (30-35 Gy/10 fractions) did not exhibit a significant increase of IMT (compared 
to the non-irradiated side),26 whereas 26 head and neck cancer patients, treated with 
high dose irradiation (50-60 Gy/ 20-25 fractions) showed a significant increase of IMT 
compared to the non-irradiated side.26
Limitations of the presented studies on radiation induced stroke 
Strong elements of the three presented studies on stroke risk are the long-term and the 
relatively complete follow-up. However, a potential weakness of our studies concerns 
under-reporting of stroke diagnoses by chart- and retrospective review. Another 
matter, which actually concerns all studies on late effects, is that results of retrospective 
studies evaluating late adverse effect of treatment regimens from the past, do not per 
se hold true for current clinical practice with newer radiation techniques (e.g. involved 
field for Hodgkin’s lymphoma) and other radiation schedules. Finally, from our studies it 
was not possible to resolve whether the combination of irradiation and chemotherapy 
augments the risk of stroke. 
Clinical implications
On the basis of our studies it is clear that subgroups of cancer survivors are at risk 
for late treatment-related effects. Especially those patients in whom longer lengths 
of the carotid artery were irradiated (head and neck patients and Hodgkin lymphoma 
survivors) carry an increased risk of stroke. This is even more pronounced when patients 
are treated with RT at a young age and in the presence of other cerebrovascular risk 
factors (i.e. hypertension, diabetes mellitus) (chapter 2.1 and 2.3).
Instead of advocating a change in current treatment regimens, we merely would like 
to make physicians aware of these already long-time under-estimated complications. 
In addition, the fact that other risk factors for cerebrovascular disease augment the risk 
for stroke implies that physicians should screen intensively for these risks and advise 
on cerebrovascular risk factor modulation by e.g. more exercise, stop smoking and/or 
healthier diet. The latter may have played an important role in the observed decreased 
risk of stroke among our breast cancer survivors (chapter 2.2).
When survivors of cancer, who have been treated with mantle or neck irradiation, 
display symptomatic carotid disease (TIA and stroke), we advise to screen the carotid 
arteries for stenosis and to explore the heart for sources of cardio-embolisms.  When a 
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symptomatic carotid stenosis of more than 50% is detected, our advice is to evaluate 
surgical risks. When patients have a low risk profile (e.g. no cardiac disease, no neck 
operation), a carotid endarterectomy can safely be performed.32 In case of high surgical 
risk (e.g. former neck operation, fibrosis of the neck after radiotherapy, a long delay 
between irradiation and symptomatic disease), we would suggest carotid angioplasty 
and stenting (CAS). This technique may prevent new cerebrovascular events from 
occurring (chapter 4.1). During follow up, regular screening (e.g. every 6 months) of 
the stented or operated carotid artery and contralateral carotid artery is necessary. 
This as, firstly, after irradiation there is an increased risk of restenosis with the presently 
applied duplex criteria, and secondly, the contralateral carotid artery may also become 
symptomatic (chapter 4.1). However, physicians should be cautious when the duplex 
outcome is “restenosis” since the present duplex criteria are yet not validated for 
stented carotids. One should therefore always confirm the duplex using other imaging 
techniques like CT-angio, MR-angio or conventional angiography. A recent study 
comparing present duplex criteria, with confirmation by conventional angiography 
showed that duplex velocities are much higher in stented arteries than in non-stented 
ones.33 New follow-up studies with validated duplex criteria should become available 
within the coming years. For stented carotid arteries after irradiation, the follow up 
results on restenosis should then be reassessed.
Recommendations for further research
“Ignoti nulla cupido” is definitely true for late treatment related effects: in other words 
these complications have longtime been neglected due to unawareness. Further insight 
and attention for late complications has increased during the last two decades. 
Especially childhood survivors have been studied intensively in large cohorts studies 
during the last years. The results have led to a broad insight in complications and 
quality of life for these survivors.34-36 We would strongly support such a systematic 
screening for adult long-term survivors in order to gain more insight and knowledge 
on late complications and quality of life. Patients should ideally be screened and, if 
possible, treated by professionals within the field of late complications e.g. a radiation 
oncologist and other organ specific specialists, like cardiologists and neurologists, in 
case of specific complications.
Further research on preventive measurements is warranted. With the launch of the 
open-label trial on statin treatment in the reduction of IMT-progression (chapter 
5.1), we are the first to clinically explore the possibilities of reducing late occurring 
vascular complications after irradiation. If statins are effective in IMT-reduction for 
neck irradiation, this preventive treatment could be offered to other groups of cancer 
patients with expected long term survival and who received irradiation to large arteries 
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and to the heart. Since randomized clinical trials often require to include large numbers 
of patients, it is important  to be able to explore new preventive treatments in animal 
models. At the present, animal models are available for studying radiation induced 
arterial- and cardiovascular disease. Studies in hypercholesterolemic rabbits and mice 
have found that irradiating large arteries accelerates the formation of atherosclerotic 
plaque.37-39 New research initiatives could focus on other treatment options that have 
shown to diminish atherosclerosis by improving endothelial function such as ACE-
inhibitors, new anti-inflammatory drugs or endothelial progenitor cells. 40,41
Finally, in the future more insight in the DNA-profile will help us to study and define 
subgroups of patients who are at possible risk for specific late effects. We know that 
patients vary considerably in their responses to radiation and it is the tolerance 
of the more sensitive subjects that limits the dose that can be given to the patient 
population as a whole. This may limit the chance of tumor cure in some cases. At least 
some of this variation is genetically determined, which therefore stimulates research 
into identifying those patients who are more susceptible for radiation damage.42,43
I hope that this thesis will challenge us all in recognizing and preventing late-treatment 
related effects, improving cancer treatment and thereby ameliorate the long-term well 
being of cancer patients! 
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Kanker treft één derde van alle mannen en één kwart van alle vrouwen in de 
Nederlandse populatie. Met de steeds verbeterende behandelingsmogelijkheden 
is de prognose van kankerpatiënten de afgelopen decennia aanzienlijk verbeterd; 
kanker kan hiermee in sommige gevallen een chronische ziekte worden. Door de 
verbeterende overleving is er meer aandacht gekomen voor late therapiegerelateerde 
complicaties. Late therapiegerelateerde complicaties betreffen o.a. het optreden van 
tweede tumoren, fertiliteitstoornissen maar ook (cardio-) vasculaire complicaties. Een 
belangrijke late cardiovasculaire complicatie is het herseninfarct. 
Deze late therapiegerelateerde complicaties hebben vaak een belangrijke impact op 
het dagelijks functioneren en de kwaliteit van leven van patiënten nadat zij curatief 
behandeld zijn voor hun primaire maligniteit. Kennis over de late therapiegerelateerde 
complicaties is dan ook van essentieel belang in het kader van eventuele 
behandelingsmodificaties maar ook om uit te zoeken of deze complicaties voorkomen 
kunnen worden door preventieve maatregelen. Ten slotte is het van belang patiënten 
vóór aanvang van de behandeling een goede voorlichting te geven over de eventuele 
late therapiegerelateerde complicaties.
De belangrijkste vragen die in dit proefschrift worden onderzocht zijn: (I) welke 
risicofactoren bestaan er voor bestralingsgeïndiceerde vasculopathiëen en het 
hieraan gerelateerde herseninfarct en wat is de incidentie hiervan, (II) hoe kan 
bestralingsgeïnduceerde carotisstenose behandeld worden en (III) bestaat er 
een preventieve behandeling om bestralingsgeïnduceerde vasculopathiëen te 
voorkomen?  
In hoofdstuk 2.1 wordt een klinische studie beschreven over de incidentie van 
herseninfarcten bij patiënten die bestraald zijn op het halsgebied vanwege een 
larynxcarcinoom (n=162), een pleiomorfadenoom (n=114) of een parotiscarcinoom 
(n=91). De patiënten werden bestraald vóór de leeftijd van 60 jaar en werden 
gemiddeld 7,7 jaar gevolgd (3011 persoonsjaren). Gegevens over het optreden van 
een herseninfarct werden verzameld door statusonderzoek of door het opvragen van 
informatie bij de huisarts. In deze patiëntengroep werd een bijna zes keer verhoogd 
risico op een herseninfarct gevonden (Relative Risk (RR) 5.6; 95% confidence interval 
(CI) 3.1-9.4) ten opzichte van een voor leeftijd- en geslacht gecorrigeerde groep uit 
de algemene populatie. Voor elke afzonderlijke patiëntengroep bleek een verhoogd 
risico op het ontwikkelen van een herseninfarct te bestaan: patiënten met een 
larynxcarcinoom hadden een relatief risico (RR) van 5.1 (95% CI 2.2-10.1), bij patiënten 
met een pleiomorfadenoom werd een RR van 5.7 (95% CI 1.5-14.5) gevonden en 
bij parotiscarcinoom patiënten vonden we een RR van 8.5 (95% CI 1.0-30.6). De 
aanwezigheid van de bijkomende risicofactoren diabetes mellitus en hypertensie 
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resulteerden in een verdere toename van het risico op een herseninfarct. Gedurende 
de jaren na de bestraling nam het risico op een herseninfarct cumulatief toe: na 15 jaar 
was dit gestegen tot 12%.
In hoofdstuk 2.2 beschrijven we het behandelingspecifieke risico op cerebrovasculaire 
aandoeningen (CVA; herseninfarct, hersenbloeding en transient ischaemic attack 
(TIA)) in 4414 patiënten uit de “Late Effects Breast Cancer Study” die langer dan 
10 jaar overleefden. Over het geheel genomen was het risico op een CVA in de 
studiepopulatie 25% lager dan in de algemene bevolking. Voor patiënten bestraald 
op het supraclaviculaire en/of het parasternale gebied was het risico op een CVA niet 
verhoogd (Hazard Ratio (HR) 1.0; 95% CI  0.7-1.6) ten opzichte van patiënten die niet met 
radiotherapie werden behandeld of die werden bestraald op velden gelegen buiten 
de supraclaviculaire of parasternale regio. Een toegenomen risico op een CVA werd 
gevonden bij vrouwen die met hormonale therapie (tamoxifen) waren behandeld, 
en bij vrouwen met hypertensie of hypercholesterolemie. De gevonden HR in deze 
groepen bedroeg respectievelijk 1.9, 2.2 en 1.6.
Uit deze resultaten blijkt dat lange termijn overlevenden van een mammacarcinoom 
geen verhoogd risico hebben op een CVA in vergelijking met de algemene bevolking. 
Hormonale behandeling is wel geassocieerd met een verhoogd risico op een CVA. 
Bestralingsvelden waarin de arteria carotis is gelegen tonen geen verhoogd risico op 
een CVA ten opzichte van andere bestralingsvelden.
In hoofdstuk 2.3 wordt het risico op een CVA in een groep van 2201 overlevenden 
van een Hodgkin lymfoom beschreven. Deze patiënten werden behandeld voor het 
Hodgkin lymfoom vóór hun 51e levensjaar en werden gevolgd vanaf 5 jaar na de 
behandeling. Na een mediane follow-up van 17,5 jaar hadden 96 patiënten een CVA 
of TIA doorgemaakt: 55 patiënten maakten een CVA door, 31 patiënten een TIA en 10 
patiënten zowel een TIA als een CVA. Van de 65 patiënten die een CVA doormaakten 
betrof het in 57 gevallen een herseninfarct en in 7 gevallen een hersenbloeding (1 
incident ongedefinieerd). Bij de meeste herseninfarcten (36%) was de oorzaak gelegen 
in de grote vaten (large-atherosclerotic subtype) en in 24% bleek er sprake van een 
cardiale emboliebron. 
Hodgkin lymfoom patiënten bleken een ruim twee keer zo hoog risico te hebben op het 
ontwikkelen van een herseninfarct (HR 2.2; 95% CI 1.7-2.8) en een drie keer verhoogd 
risico op een TIA (HR 3.1; 95% CI 2.2-4.2) ten opzichte van de algemene bevolking. In de 
jaren na de behandeling neemt het cumulatieve risico op een herseninfarct en/of TIA 
verder toe (7% na 30 jaar follow-up). Bij behandeling van patiënten op jonge leeftijd 
(< 21 jaar) bleek het risico op een herseninfarct en/of TIA extra verhoogd. Bestraling 
op de hals en het mediastinum (de zogenaamde mantelveld bestraling) was een 
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onafhankelijke risicofactor voor het ontwikkelen van een herseninfarct en/of TIA. Ten 
slotte, bleek dat patiënten die een cardiale aandoening (hartfalen, ritmestoornissen, 
myocardinfarct, kleplijden) ontwikkelden, hierna een twee keer zo hoog risico op het 
optreden van een herseninfarct en/of TIA hadden. 
Samenvattend blijken Hodgkin lymfoom patiënten een verhoogd risico te hebben op 
een herseninfarct en een TIA; dit verhoogde risico is met name aanwezig bij patiënten 
die een mantelveldbestraling ondergaan (waarbij het hart en de carotiden in het 
bestralingsveld gelegen zijn), en wanneer behandeling plaatsvindt op jonge leeftijd 
(< 21 jaar). 
In hoofdstuk 3.1 is onderzocht of het verhoogde risico op een herseninfarct te wijten 
is aan de levensstijl van patiënten met een maligniteit in het hoofd/hals-gebied 
(verhoogd rookgedrag en alcoholconsumptie) of dat dit gerelateerd is aan bestraling 
op het halsgebied. Patiënten die unilateraal werden bestraald voor een hoofd-hals 
tumor ondergingen een duplex meting van de arteria carotis communis (ACC) of van 
de arteria carotis interna (ACI), afhankelijk van het bestralingsveld. Door de bestraalde 
arteria carotis te vergelijken met de niet bestraalde, contralaterale arteria carotis werd 
een interne controle bewerkstelligd en werd voor andere risicofactoren gecorrigeerd. 
Van 42 opeenvolgende patiënten werd de binnenste vaatwand dikte (intima-media; 
IMT) door middel van duplex onderzoek bestudeerd. De mediane leeftijd ten tijde van 
de diagnose en behandeling was 47,4 jaar. Patiënten werden na een mediane follow-
up van 9,8 jaar geanalyseerd. Aan de bestraalde zijde werd een significante toename 
van de IMT waargenomen ten opzichte van de niet-bestraalde zijde (1,13 mm versus 
0,83 mm, gemiddelde verschil 0,30 mm, 95% CI 0.03-0,57). Het verschil in IMT bleek 
veder toe te nemen bij een follow-up duur van meer dan 10 jaar en er bleek een lineaire 
relatie te bestaan tussen de follow-up duur en de toename van de IMT. Uit deze studie 
blijkt duidelijk dat bestraling een toename van vaatwanddikte geeft. 
In hoofdstuk 4.1 wordt bij 24 patiënten de behandeling middels carotis angioplastiek 
en stentplaatsing voor een symptomatische carotis stenose na bestraling bestudeerd. 
Carotis stenting kan mogelijk een goed behandelalternatief zijn voor bestraalde 
patiënten, aangezien het halsgebied van bestraalde patiënten vaak ernstig beschadigd 
is door eerdere operaties (radicale halsdissectie, tracheostomie) en door de bestraling 
zelf (huidfibrose, veranderde anatomie). Deze patiënten hebben theoretisch een 
verhoogd operatierisico als zij een carotisdesobstructie, de standaard behandeling, 
ondergaan. Gemiddeld ontwikkelden de patiënten 13 jaar na de halsbestraling 
neurologische symptomen en ondergingen daarvoor een endovasculaire behandeling 
middels stentplaatsing in de aangedane arteria carotis. Na een mediane follow-
up van 3,3 jaar ontwikkelde 1 patiënt (4%) een TIA aan de ipsilaterale zijde en trad 
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er bij 3 patiënten (12%) een TIA of herseninfarct aan de contralaterale zijde van de 
stent op. Na 3 maanden, 1 en 2 jaar had respectievelijk 17%, 24% en 42% een re-
stenose ontwikkeld (gedefinieerd als een stenose van ≥ 50%). Overigens ontwikkelde 
geen van de patiënten met een re-stenose een nieuwe TIA of herseninfarct. We 
concluderen uit deze studie dat endovasculaire behandeling middels stenting voor 
een bestralingsgeïnduceerde carotisstenose veilig lijkt met een laag risico op het 
ontwikkelen van nieuwe symptomen aan de stent-zijde.
In hoofdstuk 5.1 wordt het design van een gerandomiseerde, gecontroleerde, 
multicenter studie gepresenteerd. In deze studie wordt de hypothese getoetst of 
atorvastatine (een cholesterolverlagend medicijn) de progressie van IMT na bestraling 
kan tegengaan. De studie heeft een open label opzet waarbij de patiënten in de 
therapiegroep met dagelijks 20 mg atorvastatine worden behandeld. Patiënten, ouder 
dan 18 jaar, die bestraald gaan worden op het halsgebied vanwege een larynxcarcinoom, 
een parotistumor, een hypopharynxcarcinoom of een oropharynxcarcinoom worden 
geïncludeerd, gerandomiseerd en gedurende 2 jaar gevolgd. Vóór de bestraling, en 6 
en 24 maanden na de bestraling wordt de IMT gemeten. De primaire uitkomstmaat 
is het verschil in IMT tussen de behandelde en de niet behandelde groep. Secundaire 
uitkomstmaten zijn het optreden van TIA’s en herseninfarcten gedurende de follow-
up. Tevens worden inflammatoire markers, die mogelijk verhoogd zijn, tijdens 
bestraling en een verklaring kunnen geven voor het onderliggende pathogenetische 
mechanisme, bepaald. Een power-berekening toonde aan dat beide groepen minimaal 
uit 151 patiënten moeten bestaan om een significant verschil van 0,150 mm in IMT na 
2 jaar behandeling te kunnen vaststellen. De studie is goedgekeurd in 3 centra: het 
Nederlands Kanker Instituut/Antoni van Leeuwenhoekhuis, het Universitair Medisch 
Centrum St Radboud en het Universitair Medisch Centrum Maastricht.
Hoofdstuk 6 bevat een Engelse samenvatting en een algemene discussie over de 
resultaten van de onderzoeken beschreven in dit proefschrift en plaatst deze in een 
breder perspectief.
Samenvattend tonen de studies in dit proefschrift het volgende: (I) patiënten 
die bestraald worden op het halsgebied vanwege een hoofdhals tumor en een 
Hodgkin lymfoom hebben een verhoogd risico op een herseninfarct (II) bestraling 
lijdt tot een toegenomen vaatwanddikte en is een onafhankelijke risicofactor voor 
bestralingsgeïnduceerd vaatlijden (III) carotis stenting lijkt een goede behandeling 
voor patiënten met een symptomatische carotisstenose na bestraling (IV) ten slotte 
zal de toekomst moeten uitwijzen of bestralingsvasculopathieën voorkomen kunnen 
worden met een cholesterolverlagend geneesmiddel, zoals atorvastatine.
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Dankwoord
De resultaten beschreven in dit proefschrift zijn de opbrengst van een vruchtbare 
multidisciplinaire samenwerking. Op deze bladzijden wil ik van harte alle mensen 
bedanken die mij geholpen hebben bij de totstandkoming van dit proefschrift. In het 
bijzonder wil ik de patiënten bedanken die hebben deelgenomen aan de verschillende 
studies.
Een paar mensen verdienen een persoonlijk dankwoord:
Mijn promotores en copromotores:
Prof. dr. G.W.A.M. Padberg. Beste George, tien jaar heb ik op jouw afdeling neurologie 
gewerkt. “Onze afdeling” kenmerkt zich, onder jouw leiding, door professionaliteit, 
enthousiasme, ambitie, collegialiteit en werklust. Je hebt mij een grote mate van 
neurologische kennis en zelfredzaamheid bijgebracht. Ik dank je voor de vrijheid die 
je mij verleende in het onderzoek en voor de vele jaren prettige samenwerking.
Prof. dr. G.M.M. Bartelink. Beste Harry, jij was het die als geen ander toekomst zag in 
deze onderzoekslijn. Dankzij jouw enthousiasme en vertrouwen heb ik het onderzoek 
verder vorm kunnen geven. Ik bewonder de kritische houding die jij als radiotherapeut 
hebt tegenover de behandeling van oncologische patiënten en je innovatieve 
vermogen om deze behandeling steeds maar weer verder te ontwikkelen. 
Willem Boogerd. Beste Willem, de afgelopen 10 jaar heb ik met enorm veel plezier 
met jou samengewerkt: eerst als co-assistent, later als assistent en nu als neuroloog. 
Voor mij ben jij op vele fronten een “leidend” voorbeeld geweest. Ik bewonder jouw 
gedrevenheid, je ongekende toewijding aan de neuro-oncologie, maar bovenal 
waardeer ik je als mens. Dankzij jouw inzet, ideeën en kritische blik hebben we dit 
onderzoek opgezet en uitgevoerd. Met veel plezier kijk ik terug op mijn AvL-tijd, de 
gezamenlijke congresbezoeken en de kopjes koffie in het Slotervaart en AvL.
Arnoud Kappelle. Beste Arnoud, onze wegen hebben zich vaak gekruist: eerst samen in 
Amsterdam, daarna samen in Nijmegen. Binnenkort sla ik een andere weg in. Ik heb jou 
als copromotor en collega zeer gewaardeerd. Samen hebben we vele uren statussen 
bestudeerd en zijn we tot mooie conclusies gekomen. De link die ons onderzoek had 
met de vasculaire neurologie heeft ons beide altijd gemotiveerd en geboeid en was 
aanleiding voor leuke zijsporen. Dank voor je enthousiasmerende, relativerende en 
opbouwende steun.
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Nederlands Kanker Instituut/ Antoni van Leeuwenhoek ziekenhuis:
Prof. dr. Floor van Leeuwen en Berthe Aleman. Beste Floor en Berthe, dank voor onze 
motiverende en warme samenwerking tussen de neurologie, de radiotherapie en de 
epidemiologie. 
Maartje Hooning. Beste Maartje, met veel plezier kijk ik terug op ons mammaproject. 
Dank voor je scherpe analytische blik, de prettige samenwerking en de gezellige 
uurtjes PSOE.
Marieke de Bruin. Beste Marieke, we hadden niet durven hopen dat er zulke mooie 
resultaten uit onze studie zouden komen. Maar met jouw inzet, je vakkundige 
epidemiologische kennis en onze levendige discussies hebben we het klaar gespeeld. 
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